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Over the past 20 years, the opioid epidemic has driven large increases in poisoning deaths
throughout the United States. These three essays address unanswered questions within the
economics and public health literature focused on the opioid epidemic. In the first chapter, I
examine the relationship between health insurance and opioid related mortality. The Medicaid
expansions enabled under the Affordable Care Act are used as a natural experiment to generate
causal estimates of the impact of public insurance expansion on opioid related mortality. In the
second chapter, I explore the relationship between treatment for opioid use disorder and opioid
related mortality. Changes in access to treatment are identified using the opening and closing of
treatment facilities. This strategy enables a comparison of the estimated effect of different types
of treatment centers based on the services offered and payment type accepted by those facilities.
In the third chapter, I examine the unintended consequences of policies designed to curb misuse
of opioids. I test how the introduction of abuse-deterrent prescription opioids has impacted rates
of viral infection.

1

Three Essays on the Opioid Epidemic: Insurance, Treatment and Supply Side Policy

Mark McInerney

B.A., Hobart and William Smith Colleges, 2012
M.A., University of Connecticut, 2016

A Dissertation
Submitted in Partial Fulfillment of the
Requirements for the Degree of
Doctor of Philosophy
at the
University of Connecticut

2019
i

Copyright by
Mark McInerney

2019
ii

APPROVAL PAGE
Doctor of Philosophy Dissertation

Three Essays on the Opioid Epidemic: Insurance, Treatment and Supply Side Policy

Presented by
Mark McInerney, B.A., M.A.

Major Advisor ___________________________________________________________________
David Simon

Associate Advisor ___________________________________________________________________
Kenneth A. Couch

Associate Advisor ___________________________________________________________________
Resul Cesur

University of Connecticut
2019
iii

Table of Contents
Chapter 1. Medicaid Expansion and the Opioid Epidemic: How does increasing health insurance impact
the crisis? ...................................................................................................................................................... 1
1. Introduction........................................................................................................................................... 1
2. Policy Background ................................................................................................................................ 2
2.1 Mechanisms..................................................................................................................................... 3
2.2 The Opioid Epidemic ...................................................................................................................... 6
3. Data ...................................................................................................................................................... 9
4. Identification Strategy ......................................................................................................................... 11
5. Results ................................................................................................................................................. 14
5.1 Robustness..................................................................................................................................... 15
5.2 Parallel Trends and Validity of Identification Strategy ................................................................ 16
5.3 Illicit Fentanyl ............................................................................................................................... 17
6. Discussion ........................................................................................................................................... 18
6.1 Measurement Error and Polysubstance Use................................................................................. 19
7. Conclusion .......................................................................................................................................... 21
8. References ........................................................................................................................................... 23
9. Tables and Figures ............................................................................................................................. 28
Chapter 2. Opioid Use Disorder Treatment and Mortality: Evidence from Variation in Services Offered 43
1. Introduction......................................................................................................................................... 43
2. Literature Review ................................................................................................................................ 44
2.1 SUD Treatment and Health Insurance.......................................................................................... 45
2.2 Efficacy of Methadone and Buprenorphine .................................................................................. 47
2.3 Access to Treatment and MAT ...................................................................................................... 48
3. Data .................................................................................................................................................... 50
4. Identification Strategy ......................................................................................................................... 52
5. Results ................................................................................................................................................. 53
5.1 Analysis of Treatment Episode Data Set: Admissions .................................................................. 55
5.2 Event Study Analysis ..................................................................................................................... 56
5.3 Robustness..................................................................................................................................... 57
5.4 Heterogeneity ................................................................................................................................ 58
5.5 Other Economic Outcomes ........................................................................................................... 59
6. Conclusion .......................................................................................................................................... 59
7. References ........................................................................................................................................... 61
8. Tables and Figure ............................................................................................................................... 66
iv

Chapter 3. The Introduction of Abuse-Deterrent Opioids and Rates of Viral Infection ............................. 85
1. Introduction......................................................................................................................................... 85
2. Background ......................................................................................................................................... 85
2.1 Viral Hepatitis ............................................................................................................................... 86
2.2 HIV ................................................................................................................................................ 89
3. Data .................................................................................................................................................... 91
4. Identification Strategy ......................................................................................................................... 92
5. Results ................................................................................................................................................. 93
6. Conclusion .......................................................................................................................................... 95
7. References ........................................................................................................................................... 96
8. Tables and Figures ........................................................................................................................... 100
I. Appendix to Chapter 1 ....................................................................................................................... 114
II. Appendix to Chapter 2...................................................................................................................... 124

v

Chapter 1. Medicaid Expansion and the Opioid Epidemic: How does increasing
health insurance impact the crisis?
1. Introduction
In 2017, about 130 Americans died as a result of an opioid overdose per day (CDC,
2018). Keith Humphreys, an addiction specialist at Stanford, recently said: “…even if you
ignored deaths from all other drugs, the opioid epidemic alone is deadlier than the AIDS
epidemic at its peak” (Ingraham, 2017). As the crisis has unfolded, the Patient Protection and
Affordable Care Act (ACA) of 2010 began a dramatic reshaping of the American health care
system. Integral to the law was expansion of health insurance access and more robust
requirements for coverage of mental health and substance use disorder (SUD) treatments. The
role of the American medical system in contributing to the opioid epidemic raises important
questions about individuals who gained health insurance coverage and misuse of opioids. I
consider two channels through which the expansion of health insurance may impact the opioid
epidemic: increased access to treatment for opioid use disorder (OUD) and increased access to
prescription opioids. This study fills a gap in the literature by examining each subcategory of
opioid related mortality available from the Centers for Disease Control and Prevention (CDC)
multiple cause of death file. I use a difference-in-differences model to estimate the causal impact
of public health insurance expansion resulting from the ACA on opioid overdose deaths by using
variation in Medicaid expansions across states and over time. I find that the Medicaid expansions
led to decreases in heroin related overdose deaths and increases in methadone related overdose
deaths. Understanding these effects is of particular importance given recent legislative proposals
to alter or repeal the ACA and the increasing severity of the opioid epidemic.
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Because the expansion of Medicaid may have both positive and negative impacts on
opioid related deaths, I examine each type of opioid mortality individually. Using this
disaggregation approach, I attempt to disentangle the effects of the Medicaid expansions on
opioids that Medicaid may fund (opioid analgesics, methadone, etc.) and opioids that Medicaid
will not fund (heroin, illicit fentanyl, ect.). If the Medicaid expansions impact opioid related
mortality in both directions, the effects may only be statistically detectable when looking at
individual categories of cause of death.

2. Policy Background
One of the primary goals of the ACA was to increase access to health care for the large
number of uninsured individuals in the U.S. Toward this goal, the ACA increased the minimum
income requirement for Medicaid coverage to 138% of the federal poverty level. As a result of a
2012 Supreme Court decision, the decision to expanded Medicaid was left to states. 36 states and
Washington D.C. have adopted the Medicaid expansion to date (KFF, 2019).1 The uninsured rate
among the non-elderly population has decreased from 18.2% in 2010 to 10.5% in 2015 (KFF,
2017). Medicaid enrollment has increased by 26% nationally (KFF, 2018). Policy uncertainty
has surrounded the ACA including multiple attempts to repeal the law and the successful repeal
of the individual mandate in 2017. This policy uncertainty may have undermined potential public
health benefits of the ACA by discouraging investment in health care infrastructure,
discouraging potential beneficiaries and causing some insurers to leave the marketplace.
The ACA required states that expanded Medicaid to offer Alternative Benefit Plans
(ABP) to the newly eligible expansion population. ABPs were required by law to cover ten

1

In some cases, the expansion of Medicaid has been adopted but not implemented.
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essential health benefits including treatment for SUDs (Grogan et al., 2016). The ACA does not
specify which SUD treatment services must be offered. As of October 2017, over 74 million
individuals were enrolled in Medicaid (Centers for Medicare & Medicaid Services, 2017).
Overall, about 12% of adult Medicaid beneficiaries have a SUD (Wachino, 2015). Bachrach et
al. (2016) write: “The expansion population—largely single adults not traditionally covered
under Medicaid before the ACA—has a higher prevalence of SUDs than populations previously
eligible for Medicaid.” It is estimated that 1.6 million individuals with SUDs received health
benefits as a result of the Medicaid expansions (Grogan et al., 2016).
Medicaid is the largest source of funding for behavioral health treatment in the U.S.
(Bachrach et al., 2016). For patients with SUDs, most outcomes improve with admission to
treatment compared to those that don’t seek treatment: decreases in drug use, decreases in
criminal activity and improvements in social and occupational outcomes (National Institute on
Drug Abuse, 2012). The American Society of Addiction Medicine (ASAM) guidelines for
treatment of OUD recommend that psychosocial treatment be used in concurrence with OUD
medications (Grogan et al., 2016). Such treatments (both impatient and outpatient) and
medications can be prohibitively costly for the uninsured.
2.1 Mechanisms
Of particular concern in this study is the impact of access to health care (though
insurance) on misuse of opioids. Many current opioid users were first introduced to opioids via
legal medical channels. Cicero et al. (2014) find that among heroin users entering treatment, 75%
of users’ first opioid use came in the form of a prescription opioid and by 2010, 94% of users’
selected heroin because prescription opioids were becoming too expensive and/or hard to obtain.
It is increasingly evident that opioids obtained through the American medical system have been
3

misused by recipients and have been diverted from the medical market to the illegal non-medical
market. Powell et al. (2016) study the introduction of Medicare Part D and find that a 10%
increase in access to medical opioids led to a 14.1% increase in SUD treatment admissions and a
7.4% increase in opioid deaths. Expanding Medicaid coverage may increase the supply and
decrease the cost of prescription opioids (including OUD medications) in a given area. Through
this channel, increasing health insurance coverage may lead to misuse of opioids (analgesics,
illicit opioids or OUD medications).
The FDA has approved three medications to treat OUD: methadone, buprenorphine, and
naltrexone. These medications are used to relieve opioid withdrawal symptoms and can be used
safely over long periods of time (months or years). Buprenorphine is the most commonly
prescribed OUD medication (Wen et al., 2017). Medication Assisted Treatment (MAT) has been
shown to increase patient survival and patient retention in treatment, decrease opioid misuse and
improve other outcomes (SAMHSA, 2015). However, FDA approved OUD medications can lead
to overdose death. There were 66,592 methadone related overdose deaths in the U.S. from 19992016 (CDC Wonder, ICD-10 code T40.3 Methadone, 2018). The rate of methadone related
overdose death per 100,000 increased by 600% from 1999-2014 (Faul et al., 2017). Methadone
carries significant risk of overdose as it provides pain relief for about 4-8 hours but stays in the
body for up to 59 hours (FDA, 2006). Methadone can slow breathing and affect heartbeat.
Misuse of methadone can occur when patients take higher doses than recommended, take doses
too frequently, obtain multiple prescriptions or obtain methadone on the black market.
Methadone may be prescribed and administered under supervision or patients may be given takehome doses. Methadone misuse and diversion are particularly problematic with respect to takehome doses (SAMHSA, 2015). The chief medical officer for Medicaid in West Virginia, Dr.
4

James Becker stated: “If you use methadone responsibly and everyone is playing by the rules,
it’s a safe medication and it’s effective…But if you’re not playing by the rules, it gets out onto
the street and people die. It has a dual personality” (Vestal, 2015). Misuse of methadone may be
particularly problematic among Medicaid beneficiaries. Faul et al. (2017) find that in 2014, the
methadone prescribing rate for Medicaid enrollees was about double that of Commercial Claims
and Encounters enrollees.
Recent studies have found significant increases in admissions to specialty treatment and
prescriptions for medication use to treat SUD in expanding states relative to non-expanding
states. Meinhofer and Witman (2018) show that aggregate treatment admissions for OUD
increased by 18% in expanding states. Among Medicaid beneficiaries, opioid related admissions
increased by 113% in expanding states without crowding out beneficiaries of other insurance
types (Meinhofer and Witman, 2018). Maclean and Saloner (2019) find that Medicaid coverage
increased among patients receiving specialty treatment and Medicaid payments for specialty
treatment increased within expanding states. Further, the volume of prescriptions approved by
the FDA to treat SUD increased in expanding states (Maclean and Saloner, 2019). Wen et al.
(2017) find that the expansion of Medicaid in 2014 led to a 70% increase in buprenorphine
prescriptions covered by Medicaid and a 50% increase in Medicaid spending on buprenorphine.
Saloner et al. (2018) look across all payers (public, private and cash) and find that buprenorphine
with naloxone prescriptions increased by about 13% within counties that expanded Medicaid.
Patient access to MAT is limited in a number of ways. Cost is an important barrier for the
uninsured population. A full course of buprenorphine maintenance costs about $6,000 per patient
per year (Wen et al., 2017) while the cost of methadone maintenance is about $4,700 per patient
per year (National Institute on Drug Abuse, 2012). Medicaid benefits vary across states and may
5

not cover both medications. From 2004-2013, the number of states in which Medicaid benefits
cover both methadone and buprenorphine increased from 21 states to 32 states (Burns et al.,
2016). Beyond cost, MAT is limited by physician waivers under the Drug Addiction Treatment
Act of 2000. In order to prescribe FDA approved opioids to treat OUD, physicians must apply
with the Substance Abuse and Mental Health Services Administration (SAMHSA) for a waiver
(Jones et al., 2015). Initially, those physicians receiving the waiver can prescribe to up to 30
patients and up to 100 after one year and with a revised waiver (Jones et al., 2015). Despite these
patient limits, approximately 44-66% of physicians with the waiver do not prescribe
buprenorphine at all (Jones et al., 2015).
There are many other barriers to receiving treatment. These barriers include lack of
individual desire to stop using, a lack of awareness of treatment options or a lack of awareness of
the need for treatment (Center for Behavioral Health Statistics and Quality, 2016). Among the
population of patients aware of the need for treatment, there are other obstacles including strong
social stigma, waiting lists for admission to treatment, language barriers, transportation barriers
and others. Only a small percentage of the total population with a SUD receives treatment in a
given year, about one out of ten (Center for Behavioral Health Statistics and Quality, 2016). An
estimated 20.2 million adults in the U.S. had a SUD in 2014 (Lipari and Van Horn, 2017).
2.2 The Opioid Epidemic
The opioid epidemic is part of a broader public health crisis in the U.S. Case and Deaton
(2015) show that despite longstanding declining mortality rates, there was an increase in
mortality rates for US White non-Hispanics ages 45-55 between 1990 and 2010. Increasing
mortality rates were driven by increases in drug and alcohol poisonings and suicide (Case and
Deaton, 2015). Pain killers were traditionally prescribed for short-term use, post-surgery pain,
6

and for pain related to life threatening or terminal illnesses. In 1980, a letter to the editor in the
New England Journal of Medicine noted that patients rarely become addicted to narcotic pain
killers (Gounder, 2013). A 1986 study published in the Journal of Pain concluded that, for noncancer pain, narcotics: “can be safely and effectively prescribed to selected patients with
relatively little risk of producing the maladaptive behaviors which define opioid abuse”
(Gounder, 2013).
Purdue Pharma began manufacturing OxyContin in 1996 and started to encourage
doctors to prescribe pain killers more frequently. Kolodny et al. (2015) state: “Between 1996 and
2002, Purdue Pharma funded more than 20,000 pain-related educational programs through direct
sponsorship or financial grants and launched a multifaceted campaign to encourage long-term
use of OPRs [Opioid Pain Relievers] for chronic non-cancer pain”. By 2010, OxyContin was the
15th ranked prescription by retail sales (Alpert et al., 2018). OxyContin became over-prescribed
and widely available in the US. Some studies have identified OxyContin as one of the causes of
the opioid epidemic (Kolodny et al., 2015).
Many policies and interventions intended to curb the opioid epidemic have focused on
the supply of opioids (Alpert et al., 2018). Recent research has shown that some policies
focusing on the supply of prescription opioids have had the unintended consequence of leading
opioid users to substitute across different types of opioids. Persistent misuse of OxyContin led
Purdue Pharma to reformulate the drug in 2010. OxyContin was typically misused by crushing
pills and then injecting or inhaling (Alpert et al., 2018). Purdue Pharma introduced a pill that was
harder to crush and abuse. Evans et al. (2019) find that the rapid increase in heroin related
overdose deaths began the month after abuse-deterrent OxyContin was introduced. Alpert et al.
(2018) focus on the geographic variation in the prevalence of OxyContin misuse prior to the
7

introduction of abuse-deterrent OxyContin. The authors find that one additional percentage point
of OxyContin misuse was associated with 2.5 additional heroin deaths per 100,000 (Alpert et al.,
2018).
Many states have responded to the opioid epidemic with legislation in different forms.
Prescription Drug Monitoring Programs (PDMPs) established centralized, electronic databases
designed to curb overprescribing. PDMPs can regulate over-prescription resulting from
prescriber behavior and patient behavior. Evidence regarding the effectiveness of PDMPs and
other policies that sought to curb excessive opioid prescribing has been mixed. Bao et al. (2016)
find that enacting a PDMP was associated with about a 30% reduction in the prescribing rate of
Schedule II opioid painkillers. Kilby (2015) shows that PDMPs reduced opioid related overdose
deaths but were also associated with substitution from prescription opioids to heroin.
Buchmueller and Carey (2018) find that PDMPs have not affected prescribing rates unless they
included “must access” clauses, which the majority of PDMPs do not have. In some states, pain
clinics provided large quantities of opioid analgesics, often with little oversight or medical
justification (Dowell et al., 2016). 11 states have passed Pain Clinic Laws (PCLs) to establish
additional regulation and oversight over opioid prescribing. Dowell et al. (2016) find that the
implementation of PCLs along with PDMPs with mandated provider review decreased opioid
prescribing rates and opioid related death rates.
Naloxone (also known by the brand name Narcan) is a substance that can block or
reverse the effects of opioids in the case of an overdose. Naloxone Access Laws (NALs) make it
easier for medical professionals to prescribe and distribute Naloxone. Good Samaritan Laws
(GSLs) remove criminal liability for persons seeking to help a person in danger. Opioid overdose
deaths are generally not sudden, bystanders able to recognize an overdose can seek medical care
8

and help prevent overdose deaths (Rees et al., 2019). Rees et al. (2019) study the impact of GSLs
and NALs on opioid related mortality and find that the adoption of NALs was associated with a
9-11% reduction in opioid-related deaths. The availability of medical marijuana may also impact
opioid use. For example, in states where medical marijuana is accessible, marijuana may be
prescribed for chronic pain instead of opioid analgesics. Bachhuber et al. (2014) find that states
that passed MMLs had about a 25% lower mean annual opioid related death rate.

3. Data
The primary outcome variable used in this study is opioid related mortality. These data
were obtained from the CDC Wide-ranging online data for epidemiologic research (Wonder)
multiple cause-of-death detailed mortality files. This sample includes data from 1999-2016 at the
state, year level. Following Rees et al. (2019), I classify all opioid related overdose deaths by
International Classification of Disease, Tenth Revision (ICD-10) codes as including: T40.0
(opium), T40.1 (heroin), T40.2 (other opioids), T40.3 (methadone), T40.4 (other synthetic
narcotics) and T40.6 (other/unspecified narcotics). I consider each of these categories as
individual outcome variables (excluding opium due to the low number of deaths associated with
opium). Additionally, I consider ICD-10 code: T50.9 (other and unspecified drugs, medicaments
and biological substances) which is discussed in more detail in section 6.1. These data include
underlying cause of death codes: X40-X44 (Unintentional), X60-X64 (Suicide), X85 (Homicide)
and Y10-Y14 (Undetermined). It should be noted that any one overdose death could involve
multiple ICD-10 codes (for example, heroin and other opioids were both used by an individual
that later died). I apply the same classifications to county, year level data (2003-2016). Mortality
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data with county level identifiers were obtained from The National Association for Public Health
Statistics and Information Systems (NAPHSIS).
Second, I consider outcomes from the Centers for Medicare & Medicaid Services State
Drug Utilization data. I examine data from 2006-2016 containing methadone prescriptions
reimbursed by Medicaid at the state, quarterly level. I test three outcomes: number of
prescriptions, Medicaid amount reimbursed and units reimbursed. Medicaid State Drug
Utilization data separates prescriptions by utilization type (fee for service or managed care) and
by product code. I aggregate the data to state, quarterly level observations as follows:
𝑃𝑟𝑒𝑠𝑐𝑟𝑖𝑝𝑡𝑖𝑜𝑛 𝑠,𝑡 = ∑ 𝑌𝑖,𝑗,𝑠,𝑡

(1)

𝑖,𝑗

Where 𝑌𝑖,𝑗,𝑠,𝑡 is the number of prescriptions of product code i, of utilization type j, in state s, in
quarter t.
I control for other changes in state law designed to alleviate the opioid epidemic or that
may impact outcomes related to the opioid epidemic. These laws include NALs, GSLs, PDMPs
(including earlier substances monitoring programs), PDMPs with a must access clause, PCLs and
MMLs (hereafter referred to as other pertinent laws). The effective dates and classification of
these laws is listed in table A1. Controlling for such changes in state law can eliminate any
potential confounding impact resulting from policy change unrelated to the Medicaid expansions.
Data regarding the implementation dates of NALs and GSLs comes from Rees et al. (2019) and
the Policy Surveillance Program (2018). The effective dates of PDMPs come Kilby (2015) and
the National Alliance for Model State Drug Laws (2018). Classification and dates of PDMPs
with a “must access” clause come from Buchmueller and Carey (2018). Implementation dates of
MMLs come from Baggio et al. (2018). Effective dates of PCLs were derived from Meinhofer
10

and Witman (2018). Medicaid expansion dates come from the Kaiser Family Foundation (KFF)
and Maclean and Saloner (2019). Unemployment data was obtained from the Bureau of Labor
Statistics (state and county level). Population and demographic data (state and county level)
come from the National Center for Health Statistics (NCHS) Bridged-Race Population Estimates.
Demographic controls include the fraction of the state or county population that is female, white,
black, ages 0-15, ages 16-35 and ages 36-64. State quarterly level population data were obtained
from the Bureau of Economic Analysis Personal Income Summary.

4. Identification Strategy
I apply a difference-in-differences (DD) empirical strategy. Specifically, I estimate the
following Poisson regression:
ln(𝜆𝑠,𝑡 ) = 𝛽1 + 𝛽2 𝑀𝑒𝑑𝑖𝑐𝑎𝑖𝑑𝑠,𝑡 + 𝑋𝑠,𝑡 𝛾 + 𝛿𝑡 + 𝜇𝑠 + + 𝜀𝑠,𝑡

(2)

The outcome of interest, 𝜆𝑠,𝑡 , is the number of opioid related deaths in state s in year t. 𝑋𝑠,𝑡 is a
vector of controls including, the natural log of the state population, the state unemployment rate,
state demographics (age, gender and race) and other pertinent laws. 𝛿𝑡 is the year fixed effect,
which will capture the aggregate time trends. 𝜇𝑠 is the state fixed effect. 𝛽2 is the coefficient of
interest, capturing the impact of the Medicaid expansions on opioid related mortality.
𝑀𝑒𝑑𝑖𝑐𝑎𝑖𝑑𝑠,𝑡 is an indicator variable equal to 1 if the expansion of Medicaid was in effect in state
s and year t (𝑀𝑒𝑑𝑖𝑐𝑎𝑖𝑑𝑠,𝑡 is a fraction if in place for a portion of that year and equal to 0
otherwise). Equation 2 is weighted by total population at the state, year level. Standard errors are
adjusted for clustering at the state level.
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Of particular concern is the definition of treatment and control in the DD specification.
Previous Medicaid expansions along with differences among the early expanding states could
confound the treatment effect (Kaestner et al., 2017). Five states and Washington D.C. expanded
Medicaid prior to January 1st 2014: CA, CT, D.C., MN, NJ and WA. Within the early expanding
states, many Medicaid enrollees did not gain insurance; rather, they were shifted from county or
state level programs resulting from earlier Medicaid expansions (KFF, 2012). CA and CT did
experience large increases in enrollment following early expansion (KFF, 2012). For this reason,
CA and CT are the only states among the early expanding states included in my primary
specification while D.C., MN, NJ and WA are dropped. I consider a number of alternate
specifications to test the sensitivity of findings to the definition of treatment and control groups
(see section 5.1 for additional discussion).
Using survey data from Burns et al. (2016), I estimate a model that takes into account
differences in Medicaid benefits across states and over time. Using this model, I may more
accurately identify the treatment effect (expansion of Medicaid) with respect to access to OUD
medications. This specification is particularly pertinent when estimating models where
methadone related deaths or methadone prescriptions are the dependent variable and when
considering the channel of access to MAT for OUD. I estimate the following equation:
ln(𝜆𝑠,𝑡 ) = 𝛽1 + 𝛽2 𝑀𝑒𝑑𝑖𝑐𝑎𝑖𝑑𝑠,𝑡 ∗ 𝑀𝐴𝑇𝑠,𝑡 + 𝛽3 𝑀𝑒𝑑𝑖𝑐𝑎𝑖𝑑𝑠,𝑡 ∗ 𝑂𝑡ℎ𝑒𝑟𝑆𝑡𝑎𝑡𝑒𝑠𝑠,𝑡 + 𝑋𝑠,𝑡 𝛾 + 𝛿𝑡
+ 𝜇𝑠 + 𝜀𝑠,𝑡

(3)

Here, 𝑀𝐴𝑇𝑠,𝑡 is an indicator variable equal to 1 if buprenorphine and methadone are covered by
Medicaid in state s and year t (equal to zero otherwise). 𝑀𝑒𝑑𝑖𝑐𝑎𝑖𝑑𝑠,𝑡 ∗ 𝑂𝑡ℎ𝑒𝑟𝑆𝑡𝑎𝑡𝑒𝑠𝑠,𝑡 captures

12

the impact of the expansion of Medicaid in states in which Medicaid benefits do not cover both
buprenorphine and methadone.
The validity of this identification strategy relies on satisfaction of the common trends
assumption. I test this assumption using event study analysis. The event studies are limited in
terms of post period data as the majority of expanding states expanded Medicaid in 2014 or later.
With respect to 2014 expanding states, the data contain 3 total years of event year/post policy
period data (2014, 2015 and 2016). In specifications including CA and CT, additional post policy
period data is available. I estimate the following event study model:
3+

ln(𝜆𝑠,𝑡 ) = 𝛼 + ( ∑ 𝐸𝑆 𝑠,𝑡 ) 𝛽 + 𝑋𝑠,𝑡 𝛾 + 𝛿𝑡 + 𝜇𝑠 + + 𝜀𝑠,𝑡

(4)

𝑡=−5

Where 𝐸𝑆𝑠,𝑡 is an indicator variable equal to one in treatment state s, in year t in relation to the
policy change. I begin the event study 5 years prior to the policy change and group all
observations 3 or more years after the policy change.2 I also estimate event studies in which all
early and late expanding states are dropped.
My primary specification uses state, year level data. I present Poisson results as my
primary specification because the dependent variable of interest is a count. 3 I examine the
robustness of these results to use of county, year level data and to different distributional
assumptions about the outcome variable. I convert the outcome variable to a rate of opioid
related mortality per 100,000 in state s and in year t to estimate OLS models (including the same
controls except the log population control). The death rate is transformed using the natural log

2

I have also run event studies grouping all pre-treatment years 5 years or more prior to treatment. Event studies
appear similar in these specifications in terms of pre-trend analysis.
3
In a few instances, I force Poisson models to converge after 500 iterations if convergence is not achieved.

13

(LN) or inverse hyperbolic sine (IHS) functions.4 Prior to the log transformation, I add 1 to the
death rate per 100,000 to prevent missing observations.

5. Results
Poisson regression results presented in table 2 suggest that the expansion of Medicaid
resulted in about a 29 percent reduction in heroin related overdose deaths. The magnitude of the
finding is evident when considering the population weighted mean number of heroin related
deaths, 202 per state per year. The impact of the Medicaid expansions varies by each
subcategory of opioid related overdose death. Expansion of Medicaid was associated with a 14
percent increase in methadone related deaths in the baseline model though the coefficient of
interest is no longer statistically significant with the inclusion of a full set of controls.5 The
population weighted mean number of methadone related overdose deaths is about 140 per state
per year. The coefficient of interest is positive and significant with respect synthetic opioid
related overdose deaths in the baseline model. However, it may be the case that the rise in
prevalence of illicit fentanyl has disproportionately impacted the expanding states (see section
5.3 for additional discussion). Results in table 2 suggest that the expansion of Medicaid would
lead to a decrease of 58 heroin related deaths and an increase of 19 methadone related deaths in a
given state, in a given year. Table 3 points to access to MAT through insurance as a crucial
channel in reducing heroin deaths while also driving increases in methadone related deaths.
Increases in methadone related overdose deaths may be related to increases in methadone
treatment for OUD in expanding states, though methadone is also prescribed for chronic pain.

4

IHS transformation is considered given concerns about the LN transformation in the case that the outcome variable
is zero or close to zero
5
p-value = 0.188. If the control for MML is dropped, p-value = 0.106
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5.1 Robustness
In table 4, I reestimate equation (2) using county, year level data. Similar to the state
level results, the county level results suggest that the expansion of Medicaid led to a decrease in
heroin related overdose deaths and an increase in methadone related overdose deaths. Using
county level data, the increase in methadone related overdose deaths is significant at the 1% level
with the inclusion of a full set of controls. Next, I test the robustness of results to different
functional forms including OLS and negative binomial regression results. OLS (table 5) and
negative binomial (table A7) results show that my findings are relatively robust to different
distributional assumptions, though the OLS results are less precise. In table 5, again it appears
that reductions in heroin deaths and increase in methadone deaths were driven by the expansion
of Medicaid in states in which Medicaid benefits cover both methadone and buprenorphine.
Next, I test the robustness of these findings to alternate classifications of treatment and
control. In my primary specification, states that previously expanded Medicaid and did not
experience significant increases in Medicaid enrollment (D.C., MN, NJ and WA) are dropped
from the sample. In table A2, I consider 3 alternate methods of coding the Medicaid expansions.
In row (1), I include all 50 states plus D.C. and define Medicaid expansion dates as shown in
table 8. In row (2), I include all 50 states (plus D.C.) and assign Medicaid expansion dates based
on increases in Medicaid enrollment following Meinhofer and Witman (2018). Among the early
expanding states that expanded Medicaid more than once, Meinhofer and Witman (2018) select
the date of expansion as the expansion that led to the largest increase in enrollment. In row (3),
results are shown from my primary specification (D.C., MN, NJ and WA are dropped from the
sample). In row (4), Oregon and Massachusetts are dropped as both states established health care
reforms and increased access to health insurance including expansion of public insurance prior to
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the Medicaid expansions. Results appear robust across these 4 methods of coding treatment and
control.
Regression results are weighted by population. Primary results are robust when weighted
by population (table 2) or unweighted (table A8). As an additional robustness check, I reestimate the impact of the expansion of Medicaid on heroin related overdose deaths by dropping
each treatment state individually (all early expanding states are included in this sample). The
estimated treatment effect remains relatively stable with the exception of the specification in
which California is dropped (table A6).6
5.2 Parallel Trends and Validity of Identification Strategy
The validity of the estimates presented rests on satisfaction of the parallel trends
assumption. The parallel trends assumption is examined using visual evidence in the form of
event study analysis. The event studies do not, in general, exhibit significant pre-trends. Pretrends are of particular concern given the politicization of the ACA and the decision to expand
Medicaid. I present event studies of two types. In figures 2 and 3, I utilize variation in the timing
of Medicaid expansion including late expanding states and early expanding states (CA and CT
only). In this specification, the event year varies among the early and late expanding states.
Figure 2 reveals no visible pre-trends with respect to heroin related overdose deaths. Figure 3
reveals some visible changes in the pre-policy period with respect to methadone related deaths,
though a treatment effect appears visible in the post policy period. In the second type of event
study, all early and late expanding states are dropped from the sample. The treatment group
includes only states that expanded Medicaid in 2014 and the control group includes all non6

California represents the largest treatment state in my study both in terms of population and change in insurance
status with over 2.5 million individuals gaining health insurance by 2017 (KFF, 2017)
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expanding states. In figures 4 and 5, confidence intervals are centered around or include a zero
coefficient estimate in the pre-policy period. Following the expansion of Medicaid, heroin deaths
appear to decrease (figure 4) and methadone deaths appear to increase (figure 5).
5.3 Illicit Fentanyl
In recent years, the increasing prevalence of illicit fentanyl in the U.S. has contributed to
further increases in opioid mortality. Fentanyl is a synthetic opioid that is approximately 80-100
stronger than morphine (DEA, 2019). Fentanyl related overdose deaths began to dramatically
increase around 2014 (see figure 1). The majority of expanding states expanded Medicaid in the
same year. Unless there is a causal relationship between the expansion of Medicaid and rise in
illicit fentanyl, the geographic distribution of illicit fentanyl may have differentially impacted the
expansion states. From 2013-2014, the states with the largest increase in the synthetic opioid
related death rate (excluding methadone) were Ohio, Massachusetts, Maryland and New
Hampshire (Gladden et al., 2016). All four of these states expanded Medicaid in 2014. To the
extent that there is no causal relationship between expansion of Medicaid and the distribution of
illicit fentanyl, this is a confounding trend which most likely introduces downward bias in the
estimated public health benefits of the expansion of Medicaid.
In table 7, I test alternate specifications to account for the rise of illicit fentanyl. In the
baseline model (row 1) the expansion of Medicaid is associated with a significant increase in
synthetic opioid related overdose deaths. With the inclusion of controls for other pertinent laws
(row 2), the coefficient of interest is large in magnitude but no longer statistically significant. In
row (3), those states that experienced the largest increase in the synthetic opioid related death
rate (OH, MA, MD and NH) are dropped from the sample. After these four states are excluded,
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the expansion of Medicaid no longer appears to have explanatory power with respect to synthetic
opioid deaths (excluding methadone). Following Meinhofer and Witman (2018), I include data
from the Drug Enforcement Agency National Drug Threat Assessment (NDTA) to control for
the per capita rate of seizures of illegally manufactured fentanyl. In row (4), inclusion of the
control for fentanyl seizures removes the explanatory power of the Medicaid expansions with
respect to synthetic opioid related overdose deaths. States in the Northeastern U.S. have been
particularly hard hit by illicit fentanyl. In table A4, I consider two separate subsamples excluding
states in the North East. The primary results presented in the study appear robust to the exclusion
of these states. Yet in the smaller subsample, again, no relationship appears between the
expansion of Medicaid and increases in fentanyl related deaths.

6. Discussion
Recent studies (Meinhofer and Witman, 2018; Maclean and Saloner, 2019; Saloner et al.,
2018, Wen et al., 2017) have shown increases in prescriptions used to treat OUD and specialty
treatment admissions in states that expanding Medicaid. Reductions in opioid related overdose
deaths within the expanding states are most likely explained by increased access to treatment and
prescriptions used to treat OUD. Maclean and Saloner (2019) do not include methadone in their
study as methadone is prescribed for uses other than treatment of OUD. Results in table 6 show
that the expansion of Medicaid was associated with a 20-37 percent increase in methadone
prescriptions reimbursed by Medicaid, depending on the outcome variable (number of
prescriptions, amount reimbursed or units reimbursed). The coefficient of interest increases in
magnitude as estimated by equation (3). In other words, methadone prescriptions increased in
states that expanded Medicaid in which Medicaid benefits cover methadone. These increases in
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methadone prescriptions in expanding states are visible in figures 6 and 7. Results in table 6 are
suggestive of increased utilization of methadone therapy for OUD in expanding states relative to
non-expanding states. However, methadone is commonly prescribed for chronic pain,
particularly in cancer patients.
Results in tables 3 and 6 point to the public health benefits associated with increased
access to MAT as well as the potential consequences associated with increasing access to
methadone. Analyzing cause of death by ICD-10 codes enables the separation of methadone
deaths and other synthetic opioid deaths. However, ICD-10 code T40.4 can include fentanyl,
propoxyphene, meperidine, or buprenorphine (Kilby, 2015). The methodology used in this study
does not allow for the separation of deaths caused by fentanyl or buprenorphine. In general,
buprenorphine is considered to be a safe medication. There may be some consequences
associated with increased access to buprenorphine. The Tennessee Department of Health recently
found that some deaths were associated with misuse of buprenorphine and use of buprenorphine
in concurrence with other prescription or illicit drugs (Tennessee Department of Health, 2018).
6.1 Measurement Error and Polysubstance Use
A major obstacle to the disaggregation approach used in this study is the prevalence of
polysubstance use or the use of multiple substances by a single user. It is quite common for those
struggling with OUD to use opioids of different types in concurrence or to use opioids in
concurrence with other prescription drugs, other illicit drugs and/or alcohol. Polysubstance use
can increase the risk of overdose. For example, use of benzodiazepines is known to increase the
risk of overdose death when used with opioids (Mattson et al., 2018). In an 11-state analysis
taking place from July 2016-June 2017, benzodiazepines were found present in approximately
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half of deaths categorized as prescription opioid–only deaths (Mattson et al., 2018).
Polysubstance use is a strong predictor of misuse of prescription opioids (Morley et al., 2017)
Increased access to MAT could increase the likelihood that methadone, buprenorphine or
naltrexone are present at the time of an opioid overdose. This may be more pervasive in
expanding states than non-expanding states. I investigate this issue further in table A3 by recoding methadone related deaths in a number of different ways. The county level multiple causeof-death data contain a maximum of 20 different conditions. I collect the data and recode
methadone deaths by excluding each other type of opioid related condition in the data. Across 7
methods of coding, the Medicaid expansions are still associated with a statistically significant
increase in methadone related deaths. Table A3 suggests that the increase in methadone deaths in
expanding states was not driven by the presence of methadone in opioid overdose cases
involving other opioids.
In addition to polysubstance use, measurement error presents an obstacle in this study as
misidentification of cause of death is common. ICD-10 code T50.9 classifies poisoning by
unspecified drugs, medicaments and biologicals which does not identify any specific drug. From
1999-2012, 25% of drug poisoning deaths were identified with no specific drug mentioned
(Ruhm, 2016). Svetla et al. (2015) write: "If they [coroners and medical examiners] instead write
“opioid” alone, the death will be coded to T40.6, “other and unspecified narcotics,” because the
information is not sufficient to assign a specific ICD-10 code (i.e., T40.2, “other opioids”; T40.3,
“methadone”; or T40.4, “other synthetic narcotics”). Finally, if they write simply “drug
overdose” without specifying any of the drugs involved, the contribution of the opioid analgesic
will not be reflected in how the death is coded. The death will instead receive a code of “other
and unspecified drugs” (T50.9)." A significant number of opioid related deaths are
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miscategorized in this way (Ruhm, 2016). For this reason, I consider deaths classified by ICD-10
code T50.9. In table A9, whether grouping all opioids and unspecified drugs, medicaments and
biologicals deaths (ICD-10 Codes T40.0-T40.4, T40.6 & T50.9) or all opioids (ICD-10 Codes
T40.0-T40.4, T40.6), the estimated treatment effect is similar.

7. Conclusion
This study builds on recent research (Meinhofer and Witman, 2018; Maclean and
Saloner, 2019; Saloner et al., 2018; Wen et al., 2017) which documents increases in admissions
to treatment and prescriptions for medications used to treat OUD in states that expanded
Medicaid. I find that the Medicaid expansions led to a decrease in heroin related overdose deaths
and an increase in methadone related overdose deaths. This study contributes to our
understanding of the relationship between Medicaid and the opioid epidemic but faces important
limitations including measurement error. I build further on recent research by presenting
evidence of increases in methadone prescriptions covered by Medicaid in expanding states. This
is the most likely channel (expanded access to treatment and medications for OUD) through
which the expansion of Medicaid may reduce opioid related deaths. At the same time, increasing
access to MAT can increase the diversion or misuse of these medications.
An estimated 2.1 million Americans had an OUD in 2016 (SAMHSA, 2017). In 2015, an
estimated 441,000 non-elderly adults were uninsured and addicted to opioids (Zur, 2017). Cost is
one of many barriers to receiving treatment that individuals with OUD face, particularly those
that lack health insurance. As Saloner and Barry (2018) note, targeting the supply of opioids may
impact the number of newly addicted individuals but does not sufficiently alleviate the risk of
overdose among the population already struggling with OUD. Evidence presented in this study
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could inform future demand-oriented policy to alleviate the opioid epidemic. Demand-oriented
policy could include patient outreach, education about the most effective types of treatment for
OUD and increasing access to treatment for OUD.
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9. Tables and Figures
Table 1: Weighted Summary Statistics
Variable
Mean
Std. Dev
State Level (1999-2016)
All Opioids
819.74
650.80
All Opioids rate per 100k
6.76
4.43
Heroin (T40.1)
201.86
237.48
Heroin rate per 100k
1.57
1.92
Other Opioids (T40.2)
362.43
333.83
Other Opioids rate per 100k
2.89
2.21
Methadone (T40.3)
140.14
120.66
Methadone rate per 100k
1.21
0.85
Synthetic Opioids (T40.4)
136.49
233.69
Synthetic Opioids rate per 100k
1.25
2.23
Other/Unspecified Narcotics (T40.6)
112.89
121.85
Other/Unspecified Narcotics rate per 100k
0.96
1.21
Medicaid Expansion
0.13
0.33
County Level (2003-2016)
All Opioids
70.39
107.40
All Opioids rate per 100k
7.20
6.89
Heroin (T40.1)
21.79
48.24
Heroin rate per 100k
1.76
3.03
Other Opioids (T40.2)
28.95
47.34
Other Opioids rate per 100k
3.08
3.62
Methadone (T40.3)
9.65
13.25
Methadone rate per 100k
1.28
1.78
Synthetic Opioids (T40.4)
11.23
34.99
Synthetic Opioids rate per 100k
1.42
3.28
Other/Unspecified Narcotics (T40.6)
11.35
40.76
Other/Unspecified Narcotics rate per 100k
0.87
1.81
Medicaid Expansion
0.16
0.37
Notes: Sample excludes early expanding states with previous expansions of
Medicaid (DC, MN, NJ and WA)
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Table 2: Impact of Medicaid Expansion of Opioid Related Deaths
All
Heroin
Other Opioids
Opioids

Methadone

Synthetic

Other
Narcotics

Baseline

0.115**
(0.0565)

-0.272**
(0.133)

0.0448
(0.100)

0.137**
(0.0671)

0.237*
(0.131)

0.00559
(0.145)

Controls for Pertinent Laws

0.0789
(0.0500)

-0.348***
(0.122)

0.00457
(0.0816)

0.0796
(0.0604)

0.121
(0.148)

0.0127
(0.0897)

Controls for Fentanyl Seizures

0.0344
(0.0490)

-0.348***
(0.130)

0.00637
(0.0830)

0.0785
(0.0650)

0.0304
(0.144)

-0.0627
(0.0836)

819.74
846

201.86
846

362.43
846

140.14
846

136.49
846

112.89
846

Mean of Dependent
N

Notes: State year level data: 1999-2016. Population weighted Poisson regression estimates. Models include year fixed effect
and state fixed effect. Expanding states with previous expansion have been dropped from the sample (DC, MN, NJ and WA).
Controls include the natural log of the state population, age and demographic controls and the unemployment rate. Standard
errors in parentheses are clustered at the state level. * p<0.10, ** p<0.05, *** p<0.01
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Table 3: Interaction
All Opioids

Heroin

Other
Opioids

Methadone

Synthetic

Other
Narcotics

Medicaid Expansion*MAT

0.140**
(0.0674)

-0.362***
(0.125)

0.0478
(0.105)

0.139**
(0.0680)

0.264**
(0.129)

0.189
(0.130)

Other Expanding States

-0.0384
(0.0758)

0.256*
(0.141)

0.0349
(0.167)

0.140
(0.145)

0.141
(0.241)

-0.966***
(0.278)

819.74
846

201.86
846

362.43
846

140.14
846

136.49
846

112.89
846

Mean of Dependent
N

Notes: State year level data: 1999-2016. Population weighted Poisson regression estimates. Models include year
fixed effect and state fixed effect. Expanding states with previous expansion have been dropped from the sample
(DC, MN, NJ and WA). Controls include the natural log of the state population, age and demographic controls
and the unemployment rate. Standard errors in parentheses are clustered at the state level. * p<0.10, ** p<0.05,
*** p<0.01
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Table 4: Robustness to County Level Data
All Opioids

Heroin

Other
Opioids

Methadone

Synthetic

Other
Narcotics

Baseline

0.0741
(0.0780)

-0.0338
(0.233)

0.0609
(0.117)

0.400***
(0.0892)

0.425
(0.291)

-0.314
(0.250)

Controls for Pertinent Laws

0.0184
(0.0664)

-0.247*
(0.127)

0.00187
(0.0718)

0.310***
(0.0878)

0.230
(0.227)

-0.116
(0.103)

70.39
41,853

21.79
41,853

28.95
41,853

9.65
41,853

11.23
41,853

11.35
41,853

Mean of Dependent
N

Notes: County year level data: 2003-2016. Population weighted Poisson regression estimates. Models include year
fixed effect and state fixed effect. Expanding states with previous expansion have been dropped from the sample
(DC, MN, NJ and WA). Controls include the natural log of the county population, age and demographic controls
and the unemployment rate. Standard errors in parentheses are clustered at the state level. * p<0.10, ** p<0.05, ***
p<0.01
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Table 5: Robustness to Functional Form (OLS)
Heroin

Other Opioids

Methadone

Synthetic

Other
Narcotics

-0.139
(0.101)

-0.0165
(0.0834)

0.103*
(0.0540)

0.117
(0.120)

0.0532
(0.0685)

-0.0798
(0.0793)

-0.0112
(0.0646)

0.0770*
(0.0396)

0.109
(0.0966)

0.0351
(0.0509)

-0.253**
(0.111)

-0.0275
(0.0916)

0.140**
(0.0554)

0.189
(0.134)

0.134**
(0.0628)

-0.0234
(0.0944)

0.115
(0.129)

0.0113
(0.105)

0.0166
(0.0804)

-0.0647
(0.177)

-0.223
(0.181)

0.109
(0.0821)

-0.163*
(0.0887)

-0.0156
(0.0710)

0.105**
(0.0406)

0.166
(0.110)

0.0980**
(0.0471)

-0.0204
(0.0986)

0.106
(0.102)

0.00285
(0.0809)

0.0121
(0.0593)

-0.0370
(0.139)

-0.175
(0.137)

All Opioids
Inverse Hyperbolic Sine (Death Rate)
Medicaid Expansion
0.0785
(0.0724)
Natural Log (Death Rate + 1)
Medicaid Expansion
0.0841
(0.0732)
Interaction Model
Inverse Hyperbolic Sine (Death Rate)
Medicaid Expansion*MAT
0.104
(0.0828)
Other Expanding States
Natural Log (Death Rate + 1)
Medicaid Expansion*MAT

Other Expanding States

Mean of Dependent Before
6.76
1.57
2.89
1.21
1.25
0.96
Transformation
846
846
846
846
846
846
N
Notes: State year level data: 1999-2016. Population weighted OLS estimates. Models include year fixed effect and state
fixed effect. Expanding states with previous expansion have been dropped from the sample (DC, MN, NJ and WA).
Controls include pertinent laws (NALs, GSLs, PDMPs, "must access" PDMPs, MMLs and PCLs), age and demographic
controls and the unemployment rate. Standard errors in parentheses are clustered at the state level. * p<0.10, ** p<0.05, ***
p<0.01
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Table 6: Methadone - Medicaid State Drug Utilization
Data
Log Number of
Prescriptions
Dependent
Baseline
Medicaid Expansion
0.299**
(0.116)
Interaction
Medicaid*MAT
0.367**
(0.140)

Log Medicaid
Amount Reimbursed

Log Units
Reimbursed

0.179
(0.159)

0.205*
(0.116)

0.204
(0.184)

0.240*
(0.133)

Other Expanding
States

0.0772
(0.206)

0.0963
(0.220)

0.113
(0.171)

Mean of Dependent Before
Transformation
N

5,183.41

107,727.00

569,722.10

2,009

1,857

1,475

Notes: Medicaid State Drug Utilization data 2006-2016, state, quarterly level. Population weighted OLS
estimates. Model includes year fixed effect, state fixed effect and control for the natural log of population.
Quarterly Population data from Bureau of Economic Analysis Personal Income Summary 2010-2016.
Annual Population data used as a proxy (2006-2010) from NCHS Bridged Race Population Estimates.
Standard errors in parentheses are clustered at the state level. * p<0.10, ** p<0.05, *** p<0.01
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Table 7: Alternate Specifications, Dependent variable: T40.4 Other Synthetic Narcotics
Poisson

OLS - Inverse
Hyperbolic Sine

OLS - Natural
Log (Death Rate
+ 1)

0.230*
(0.128)
918

0.220*
(0.122)
918

0.187*
(0.0994)
918

0.107
(0.149)
918

0.104
(0.130)
918

0.0979
(0.104)
918

N

-0.0502
(0.152)
846

-0.00220
(0.120)
846

0.00580
(0.0929)
846

(4) Full Sample with Control
for Fentanyl Seizures per Capita
N

0.00789
(0.146)
918

-0.0150
(0.103)
918

-0.00604
(0.0792)
918

Mean of Dependent Before Transformation

136.49

1.25

1.25

(1) Baseline
N
(2) Controls for Pertinent Laws
N
(3) Drop NH, MA, OH, MD

Notes: State year level data: 1999-2016. Population weighted regression estimates. Models include year fixed
effect and state fixed effect. Controls include age and demographic controls and the unemployment rate.
Standard errors in parentheses are clustered at the state level. * p<0.10, ** p<0.05, *** p<0.01

34

Table 8: Medicaid Expansion under the ACA
State
California
Connecticut
District of Columbia
Minnesota
New Jersey
Washington
Arizona
Arkansas
Colorado
Delaware
Hawaii
Illinois
Iowa
Kentucky
Maryland
Massachusetts
Michigan
Nevada
New Hampshire
New Mexico
New York
North Dakota
Ohio
Oregon
Rhode Island
Vermont
West Virginia
Alaska
Indiana
Montana
Louisiana
Pennsylvania
Source: Maclean and Saloner (2017)

Expansion Date
7/1/2011
4/1/2010
7/1/2010
3/1/2011
4/14/2011
1/3/2011
1/1/2014
1/1/2014
1/1/2014
1/1/2014
1/1/2014
1/1/2014
1/1/2014
1/1/2014
1/1/2014
1/1/2014
4/1/2014
1/1/2014
8/15/2014
1/1/2014
1/1/2014
1/1/2014
1/1/2014
1/1/2014
1/1/2014
1/1/2014
1/1/2014
9/1/2015
2/1/2015
1/1/2016
7/1/2016
1/1/2015
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Figure 1: Annual Opioid Overdose Deaths in the U.S.

Notes: Data obtained from CDC WONDER Online Database, Multiple Cause of Death 19992016. Deaths identified by International Classification of Disease, Tenth Revision (ICD-10)
codes as follows: T40.0-T40.4, T40.6 (all opioids), T40.1 (heroin), T40.2 (other opioids), T40.3
(methadone), T40.4 (other synthetic narcotics) and T40.6 (other/unspecified narcotics)

36

Figure 2: Event Study - Impact of Medicaid Expansions on Heroin Deaths

Notes: State year level data: 1999-2016. Population weighted Poisson regression estimates.
Model includes year fixed effect and state fixed effect. Expanding states with previous expansion
have been dropped from the sample (DC, MN, NJ and WA). Controls include the natural log of
the state population, age and demographic controls, the unemployment rate and other pertinent
laws (NALs, GSLs, PDMPs, "must access" PDMPs, MMLs and PCLs). Standard errors are
adjusted for clustering at the state level.
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Figure 3: Event Study - Impact of Medicaid Expansions on Methadone Deaths

Notes: State year level data: 1999-2016. Population weighted Poisson regression estimates.
Model includes year fixed effect and state fixed effect. Expanding states with previous expansion
have been dropped from the sample (DC, MN, NJ and WA). Controls include the natural log of
the state population, age and demographic controls, the unemployment rate and other pertinent
laws (NALs, GSLs, PDMPs, "must access" PDMPs, MMLs and PCLs). Standard errors are
adjusted for clustering at the state level.
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Figure 4: Event Study - Impact of Medicaid Expansions on Heroin Deaths: 2014
Expanding States Only

Notes: State year level data: 1999-2016. Population weighted Poisson regression estimates.
Model includes year fixed effect and state fixed effect. All early and late expanding states
dropped (treatment group includes only states that expanded Medicaid on Jan 1st 2014). Controls
include the natural log of the state population, age and demographic controls, the unemployment
rate and other pertinent laws (NALs, GSLs, PDMPs, "must access" PDMPs, MMLs and PCLs).
Standard errors are adjusted for clustering at the state level.
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Figure 5: Event Study - Impact of Medicaid Expansions on Methadone Deaths:
2014 Expanding States Only

Notes: State year level data: 1999-2016. Population weighted Poisson regression estimates.
Model includes year fixed effect and state fixed effect. All early and late expanding states
dropped (treatment group includes only states that expanded Medicaid on Jan 1st 2014). Controls
include the natural log of the state population, age and demographic controls, the unemployment
rate and other pertinent laws (NALs, GSLs, PDMPs, "must access" PDMPs, MMLs and PCLs).
Standard errors are adjusted for clustering at the state level.
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Figure 6: Medicaid Amount Reimbursed for Methadone Prescriptions

Notes: Medicaid State Drug Utilization data: 2006-2016. All early and late expanding states
dropped (treatment group includes only states that expanded Medicaid on Jan 1st 2014).
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Figure 7: Medicaid Number of Units Reimbursed for Methadone Prescriptions

Notes: Medicaid State Drug Utilization data: 2006-2016. All early and late expanding states
dropped (treatment group includes only states that expanded Medicaid on Jan 1st 2014).
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Chapter 2. Opioid Use Disorder Treatment and Mortality: Evidence from Variation
in Services Offered
1. Introduction
In 2016, 2.1 million Americans struggled with opioid use disorder (OUD) (Department of
Health and Human Services, 2017). From 1999-2016, over 367,000 deaths have been attributed
to opioid overdose (CDC, 2018).7 Important questions remain regarding the effectiveness of
treatment for OUD and whether sufficient levels of treatment are accessible. Further, among the
population with OUD seeking treatment, often patients themselves do not know what type of
treatment is most effective. In this study, I examine the impact that treatment facilities are having
on the opioid related death rate within the counties they are located. I utilize variation in the
location of substance abuse treatment facilities at the county level and variation in the services
offered and insurance type accepted by those facilities to generate causal estimates of the impact
of these services on opioid related mortality. I find significant heterogeneity across different
types of treatment facilities with respect to the impact they're having on opioid related mortality.
The opening of one additional substance abuse facility offering Medication Assisted Treatment
(MAT) and accepting Medicaid reduces the county level opioid related death rate by about 0.6 to
1 percent while one additional substance abuse facility of any other type does not have a
statistically significant impact.
Swensen (2015) exploits county level variation in the number of substance abuse
treatment facilities and finds that a 10 percent increase in the number of treatment facilities leads
to a 2 percent decline in the drug related mortality rate. This study builds on Swensen (2015) by
examining the relationship between treatment centers and opioid related mortality. Further, I

7

Including IDC-10 Codes: T40.0, T40.1, T40.2, T40.3, T40.4 and T40.6
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exploit a new source of variation, that is, variation across different types of facilities. The
American Society of Addiction Medicine (ASAM) recommends MAT to treat OUD (Grogan et
al., 2016). MAT combines behavioral therapies and prescribed medications. MAT involves one
of three medications approved by the FDA to treat OUD: buprenorphine, methadone, or
naltrexone. Methadone and buprenorphine, the most commonly prescribed OUD medications,
suppress the body’s cravings to use opioids and treat opioid withdrawal. Different OUD
medications may be appropriate for different patients given differences in detox requirements,
class of medication and frequency of dosage (Jones et al., 2018).
While substance abuse treatment facilities are increasingly offering MAT services, most
facilities did not offer these services as of 2016. Jones et al. (2018) examine data from the
National Survey of Substance Abuse Treatment Services (N-SSATS) and find that in 2016, only
4,950 of the 12,029 substance abuse facilities in the US report offering any form of MAT. There
may also be a mismatch between insurance type accepted by substance abuse treatment facilities
and the coverage of patients. In 2016, 7,466 of the 12,029 substance abuse facilities in the US
reported accepting Medicaid (Jones et al., 2018). Among adult Medicaid beneficiaries, an
estimated 12 percent have a substance use disorder (SUD) (Wachino, 2015). Approximately one
out of every five Americans is covered by Medicaid (Rudowitz and Garfield, 2018).

2. Literature Review
Many studies have found improvements in patient outcomes following admission to
treatment for SUD (Darke et al., 1996; Stewart et al., 2002; Hossop et al., 2003; Lu and
McGuire, 2002; Swensen, 2015). Darke et al. (1996) find that heroin users who sought treatment
or were active in treatment faced a substantially lower risk of overdose. Stewart et al. (2002) find
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that admission to treatment led to reductions in non-fatal overdoses. Beyond the individual health
risks, SUD imposes costs on society through health care use, use of public services, crime and
traffic accidents (Maclean and Saloner, 2018). The opioid epidemic was estimated to cost the US
economy $504 billion (2.8 percent of GDP) in 2015 (The Council of Economic Advisers,
2017).From this perspective, treatment for SUD can reduce external costs. Bondurant et al.
(2018) find that the opening of a treatment facility (at the county level) leads to a reduction in
county level crime rates including homicide, aggravated assault, robbery, auto theft, and
burglary.
The opening or closing of a treatment facility impacts the availability of services to a
given patient and can alter the cost of treatment to that patient. In 2015, 89 percent of all patients
receiving treatment for a SUD received treatment in an outpatient setting (SAMHSA, 2017).
This fact highlights the importance of the location of substance abuse treatment facilities and the
potential mismatch between patient and facility with respect to services offered and insurance
type accepted. Treatment facilities may be facing capacity constraints. Rapp et al. (2006) survey
patients with SUD to identify potential barriers to receiving treatment. 20.2 percent of patients
identified difficulty getting to and from treatment (Rapp et al., 2006). 34.3 percent of patients
identified capacity constraints reporting they would be placed on a waiting list to receive
treatment (Rapp et al., 2006).
2.1 SUD Treatment and Health Insurance
Cost can be a significant barrier to receiving treatment. White treatment facilities have
traditionally relied on public grants and subsidies for funding, public and private insurance
revenue has increased in importance in recent years (Bondurant et al., 2018). The Mental Health
Parity and Addiction Equity Act of 2008 (MHPAEA) requires health insurance issuers provide
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parity of benefits with respect to mental health and substance use disorder as would be provided
for medical/surgical benefits (Centers for Medicare and Medicaid Services, 2018b). Dave and
Mikerjee (2011) leverage state differences in parity laws prior to the MHPAEA; the authors find
that state parity legislation increased treatment admissions, lowered the cost of treatment to the
individual and reduced the probability that treatment visits were uninsured (Dave and Mikerjee,
2011).
The Affordable Care Act (ACA) bolstered the MHPAEA by requiring non-grandfathered health plans to cover ten essential health benefits which include mental health and
substance use disorder treatment (Centers for Medicare and Medicaid Services, 2018a). In 2014,
as the majority of provisions of the ACA were implemented, 20.2 million Americans struggled
with a SUD (Center for Behavioral Health Statistics and Quality, 2015). The expansion of
Medicaid extended health insurance coverage to millions of Americans including 1.6 million
individuals with a SUD (Grogan et al., 2016). Private market expansions further extended
coverage to individuals with SUDs. New evidence points to unintended consequences resulting
from the ACA and MHPAEA. Increased access to treatment requires vacancies at treatment
facilities though treatment facilities may already be constrained by capacity. Maclean and
Saloner (2018) examine the Massachusetts health reform of 2006 which expanded health
insurance access and benefits with respect to SUDs. They find that the reform had little effect on
treatment quality or access to treatment (Maclean and Saloner, 2018).
More problematic may be the perverse incentives created by the ACA and MHPAEA. A
scheme which has been called the “Florida Shuffle” involves treatment centers partnering up
with brokers who find patients with SUDs and generous health insurance benefits. Treatment
centers bill insurance issuers thousands of dollars per service like urine screening or counseling
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session (Seville et al., 2017). These fraudulent treatment centers rely heavily on online searches
and advertising and generally do not offer legitimate services that patients need. These fraudulent
treatment centers have admitted patients that subsequently died of overdose (Seville et al., 2017).
2.2 Efficacy of Methadone and Buprenorphine
Methadone and buprenorphine have been thoroughly studied in the medical literature.
Mattick et al. (2009) review 11 studies that compared opioid users treated with methadone
therapy to no opioid replacement therapy. Patients were found have improved outcomes across a
number of different measures including patient retention and subsequent drug screens with
methadone therapy (Mattick et al., 2009). Patients receiving methadone maintenance were found
to have reduced criminal activity and mortality, though these results were not statistically
significant (Mattick et al., 2009). Mattick et al. (2014) review 31 different studies that test the
efficacy of buprenorphine. A series of randomized clinical trials have shown buprenorphine to be
more effective in terms of patient retention in treatment compared to placebo (Mattick et al.,
2014). Gowing et al. (2017) review 6 studies comparing buprenorphine and methadone treatment
and conclude that despite somewhat limited evidence: “Buprenorphine and methadone in tapered
doses appear to have similar efficacy in managing opioid withdrawal”. Connock et al. (2007)
find that using a flexible dosing strategy, methadone maintenance therapy led to marginally
better health gains compared to buprenorphine maintenance therapy.
Increasingly, scientific evidence points to an increased probability of success for those
with OUD receiving some type of opioid replacement therapy compared to no replacement
therapy. In a clinical trial for an extended release formulation of buprenorphine, after 24 weeks,
about 40 percent of patients receiving the treatment were abstaining from other opioid use
compared to only 5 percent of patients receiving the placebo (National Academies of Sciences,
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Engineering, and Medicine, 2018). The Prescription Opioid Addiction Treatment Study
(POATS) followed patients dependent on prescription opioids over 42 months. Throughout
multiple follow ups over 42 months, patients receiving opioid agonist therapy were found to
have better outcomes (Weiss et al., 2015). Considering the social costs associated with OUD, we
may also consider the cost effectiveness of MAT. Buprenorphine maintenance therapy costs
about $6,000 per year (Wen et al., 2017). Methadone maintenance therapy is similar in cost in an
outpatient setting. Connock et al. (2007) review of the buprenorphine and methadone literature
concludes that both buprenorphine maintenance therapy and methadone maintenance therapy are
more cost effective compared to no MAT.
2.3 Access to Treatment and MAT
Barriers to receiving treatment include capacity constraints, distance and travel
constraints and cost constraints (Gryczynski et al., 2011; Andrews et al., 2013; Rosenblum et al.,
2011; Sigmon, 2014). Jones et al. (2015) compare rates of opioid misuse to rates of treatment
capacity and find a large shortcoming in combined buprenorphine and methadone treatment
capacity. Access to buprenorphine and methadone is restricted due to the potential to misuse
these medications. Specifically, the Drug Addiction Treatment Act of 2000 restricts the number
of patients that certified physicians can treat with buprenorphine/naloxone to 30 patients in the
first year following certification and 100 in subsequent years (Blum et al., 2016). These
restrictions may be preventing patients with OUD from obtaining these medications, particularly
in rural areas in which there are a limited number of prescribers (Blum et al., 2016). Due to these
restrictions and other factors, access to MAT has not grown as quickly as the population of
Americans struggling with OUD. Access to MAT is more likely problematic in rural counties
than in urban counties. Stein et al. (2015) find that there were 11.4 opioid treatment programs
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offering buprenorphine therapy in urban counties for every one such treatment program in rural
counties.
A particular concern in this study is the potential endogeneity of services offered by
treatment facilities. For this reason, it is important to understand why treatment facilities may not
offer MAT. Beyond the limitations associated with physician waivers, Olsen (2015) offers
possible explanations for the opposition to offering MAT in the treatment community. Several
addiction specialists from the Providers’ Clinical Support System for Medication Assisted
Treatment (PCSS-MAT) identified three possibilities in the following quote from Olsen (2015):
1. Owners of “drug-free” or “abstinence-based” facilities often do not have clinical
backgrounds so have personal or ideological perspectives on addiction and its care.
2. Treatment facilities may have financial incentives for restrictive clinical policies as
relapse may result in re-admissions and additional revenue.
3. The historical context of the “drug-free” model does not adequately differentiate between
different substance use disorders. It is a useful framework for treating addiction to
alcohol where available medications have limited effectiveness, and is virtually the only
model for treating and preventing relapse to stimulants and cannabis where no
medications exist. It is not a justifiable primary framework for the treatment of opioid
addiction anymore.
Beyond the restrictions affecting provision of MAT, these stigma and financial incentives may
be contributing to a lack of patient access to MAT. Using an email survey of physicians, Huhn
and Dunn (2017) identified concerns associated with prescribing buprenorphine that physicians
acknowledged including: a lack of time for additional patients requiring MAT, a lack of belief in
the use of agonist treatment and low reimbursement for time and services offered.
Following Swensen (2015) and Bondurant et al. (2018), I will conduct a number of
ancillary tests to examine the validity of the research design. Of particular concern is the
endogeneity of the opening/closing of treatment facilities and/or the endogeneity in choice of
services offered. Grants, subsidies and public/private insurance funding for treatment is likely to
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increase as drug abuse becomes more problematic. As Bondurant et al., (2018) argue: “Assuming
these sources of financing generally increase with drug abuse and related problems, analyses of
the effect of treatment provision on drug-related outcomes may understate the actual effect of
treatment.” (Bondurant et al., 2018)

3. Data
Data regarding the location, services offered and insurance type accepted by substance
abuse treatment facilities comes from the Substance Abuse and Mental Health Services
Administration (SAMHSA) National Survey of Substance Abuse Treatment Services (NSSATS). The N-SSATS is a survey of treatment facilities and so is not a universal database of
these facilities. The response rate varies from year to year but is generally high. For example, in
2010 the response rate was 91.4 percent and in 2013 the response rate was 94 percent (NSSATS, 2018). The N-SSATS contains a directory of each responding treatment facility that
includes county identifiers and indicates what services are offered and what payment types are
accepted by the facility.
N-SSATS directories were scraped and compiled into datasets by the organization
amfAR, the Foundation for AIDs research. Services offered and payment type accepted by
treatment facilities are identified using facility codes. A treatment facility is classified as offering
some form of MAT if any of the of the following facility codes appear: BMW (Buprenorphine
Maintenance for Predetermined Time), BU (Buprenorphine Used in Treatment), BUM
(Buprenorphine Maintenance), DB (Buprenorphine Detoxification), DM (Methadone
Detoxification), METH (Methadone), MM (Methadone Maintenance), MMW (Methadone
Maintenance for Predetermined Time), UBN (Prescribes/Administers Buprenorphine and/or
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Naltrexone), VTRL (Vivitrol, Injectable Naltrexone). A treatment facility is identified as
accepting Medicaid if the facility code MD appears in the directory. Finally, this methodology is
used to characterize facilities offering buprenorphine, methadone, multiple forms of MAT and
facilities offering MAT and accepting Medicaid.

N-SSATS data is aggregated to the county, year level and merged with restricted use
county level mortality data obtained from the National Association for Public Health Statistics
and Information Systems (NAPHSIS). Opioid related deaths are identified using the
International Classification of Disease, Tenth Revision (ICD-10) codes. All opioid deaths are
classified as including ICD-10 codes: T40.0 (opium), T40.1 (heroin), T40.2 (other opioids),
T40.3 (methadone), T40.4 (other synthetic narcotics) and T40.6 (other/unspecified narcotics).
The opioid related death rate is calculated by aggregating opioid deaths to the county, year level,
then dividing by the county population obtained from the National Center for Health Statistics
(NCHS), Bridged-Race Population Estimate.
I merge these data with a set of covariates. Demographic controls come from the NCHS
Bridged-Race Population Estimate. These demographics include the fraction of the county
population that is: white, black, female, ages 0-15, ages 16-34 and ages 35-64 years old. Controls
for economic conditions include the county unemployment rate obtained from the Bureau of
Labor Statistics (BLS) Local Area Unemployment Statistics (LAUS) and county level per capita
income obtained from the U.S. Bureau of Economic Analysis (BEA) regional data.
I consider additional outcomes obtained from the Substance Abuse and Mental Health
Services Administration’s Treatment Episode Data Set: Admissions (TEDS-A). The TEDS-A
data contain records of admissions into treatment facilities. Following Maclean and Saloner
(2019), I calculate the admissions rate per 100,000. The TEDS-A indicates whether methadone
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or buprenorphine was involved in the client’s treatment plan. From 2010-2015, 7.8 percent of
admissions involved either methadone or buprenorphine (SAMHSA, 2018). The use of
methadone or buprenorphine is relatively well reported and is only missing in 4.3 percent of
admissions records from 2010-2015 (SAMHSA, 2018). While health insurance status is also
collected, from 2010-2015, insurance status is either missing or unknown for 56.8 percent of
admissions (SAMHSA, 2018). Last, I examine the local economic impact of treatment facilities
using the county level labor force participation rate from the American Community Survey
(ACS) Employment Status 1-year estimates.

4. Identification Strategy
I closely follow the identification strategy of Swensen (2015) and Bondurant et al.
(2018), which relies on plausibly exogenous variation coming from the opening or closing of a
treatment facility. I estimate the relationship between treatment facilities and the opioid related
death rate using following equation:
𝑀𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦𝑐,𝑡 = 𝛼 + 𝛽 ∗ 𝐹𝑎𝑐𝑖𝑙𝑖𝑡𝑦𝑐,𝑡−1 + 𝑋𝑐,𝑡 𝛾 + 𝛿𝐶 + 𝜌𝑇 + 𝜃𝑐,𝑡 + 𝜖𝑐,𝑡

(1)

𝐹𝑎𝑐𝑖𝑙𝑖𝑡𝑦𝑐,𝑡−1 is the number of treatment facilities in county c in year t-1. 𝛿𝐶 is the county fixed
effect and 𝜌𝑇 is the year fixed effect. 𝜃𝑐,𝑡 represents the state by year fixed effect. The
identifying variation used in this study is visible in figures 1-3 which show the counties
throughout the U.S. that experienced one or more openings of a substance abuse treatment
facility (figure 1), one or more openings of a treatment facility offering MAT (figure 2) and one
or more openings of a facility accepting Medicaid (figure 3). Whereas Swensen (2015) considers
the impact of any treatment facility, I exploit variation across treatment facilities by measuring
treatment facilities of different types as described in section 3. 𝑀𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦𝑐,𝑡 is the opioid related
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death rate per 100,000 in county c in year t. These estimates are weighted by county population.
Standard errors are adjusted for clustering at the county level. 𝑋𝑐,𝑡 is a vector of controls
including demographic controls and controls for economic conditions.
To further examine the validity of this identification strategy, I estimate the following
event study model:
5

𝑀𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦𝑐,𝑡 = 𝛼 + ∑ 𝐸𝑆 𝑐,𝑡 𝛽 + 𝑋𝑐,𝑡 𝛾 + 𝛿𝐶 + 𝜌𝑡 + 𝜃𝑐,𝑡 + 𝜖𝑐,𝑡

(2)

𝑡=−5

I define an event year as the year in which a substance abuse treatment facility opens in county c.
I include a set of dummy variables within that county for each five years before and after the
facility/facilities opening. Some counties experienced multiple openings and/or closings
throughout the sample period. For this reason, I estimate event studies of two types. First, I
estimate the impact of the opening of a treatment facility in counties in which no previous
treatment facility of that type existed. Second, I estimate the impact of the opening of a treatment
facility in counties which experienced only a single opening throughout the sample period.

5. Results
In table 2, I examine the impact of substance abuse treatment facilities offering MAT on
the opioid related death rate. The outcome variable, the opioid related death rate at the county
year level, is transformed using the inverse hyperbolic sine function rather than the natural log
function because of the non-negligible number of observations for which the outcome variable
equals zero. For each type of facility, the opening of a treatment facility offering MAT services
decreases the county level opioid related death rate. The opening of one substance abuse facility
offering MAT is estimated to reduce the county level opioid related death rate by about 0.2 to 0.6
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percent (column 1). One additional substance abuse facility offering MAT represents a 10.6
percent increase compared to the existing mean capacity. The opening of one substance abuse
facility offering MAT and accepting Medicaid is estimated to reduce the county level opioid
related death rate by about 0.6 to 0.95 percent (column 2). The opening of one substance abuse
facility offering two or more forms of MAT and accepting Medicaid has a similar estimated
effect (column 4) to the opening of one substance abuse facility offering MAT and accepting
Medicaid. Whether a treatment facility offers one or multiple forms of MAT, a facility opening
has a larger negative impact on the county death rate if that facility also accepts Medicaid.
In table 3, I compare facilities offering buprenorphine and methadone. The opening of a
treatment facility offering buprenorphine is estimated to be more impactful on the opioid related
death rate compared to the opening of a treatment facility offering methadone (columns 1 and 3).
The opening of a treatment facilities offering buprenorphine is estimated to have a larger
negative impact on the opioid related death rate if that facility also accepts Medicaid (column 2).
The opening of a treatment facilities offering buprenorphine and accepting Medicaid leads to a
reduction in the opioid related death rate of about 0.8 percent. In table 4, I compare the types of
treatment facilities estimated to be the most impactful on the opioid related death rate to all other
substance abuse treatment facilities not of that type. The opening of a treatment facility accepting
Medicaid and offering buprenorphine, some form of MAT, or two or more forms of MAT leads
to about a 0.8 to 1 percent reduction in the county level opioid related death rate (column 1). The
opening of any treatment facility not of that type does not have a statistically significant impact
on the county level opioid related death rate (column 2). The estimates are visible in figure 5.
The opening of a treatment facility accepting Medicaid and offering MAT has a much larger
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negative impact on the opioid related death rate compared the opening of a treatment facility
accepting Medicaid or offering MAT.
5.1 Analysis of Treatment Episode Data Set: Admissions
Next, I consider outcomes from the TEDS-A. The TEDS-A data does not have county
identifiers. Rather, the TEDs-A contains identifiers for the state and core based statistical area
(CBSA) of the treatment admission. First, I aggregate the TEDS-A and the N-SSATS to the state
year level and merge the two data sets. In table 5, I examine admission by the primary substance
abuse problem restricting the sample to admissions related to OUD. Facilities that offer two plus
forms of MAT and accept Medicaid had the largest impact on the opioid related admission rate.
The opening of one such facility was estimated to increase the state level OUD admissions rate
by about 0.5 per 100,000.
Second, I aggregate to the TEDS-A to the CBSA year level. Using the CBSA to FIPS
County Crosswalk file from the National Bureau of Economic Research (NBER), I match
treatment facilities with county identifiers to a CBSA. CBSA population estimates were obtained
from the U.S. Census Bureau (2019). In panel A of table 6, I restrict the TEDS-A sample to
admissions in which methadone or buprenorphine was involved in the client’s treatment plan
(hereafter referred to as admission involving MAT). Facilities offering some form of MAT and
accepting Medicaid have the largest effect on the admission involving MAT rate. The opening of
such a treatment facility is estimated to increase the admission involving MAT rate by about 0.6
per 100,000.
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5.2 Event Study Analysis
In order to test the validity of the research design, I present event studies that examine the
impact of a treatment facility opening on the opioid related death rate in each year before and
after the opening. The event study evidence, in general, alleviates concerns about the
endogeneity of the opening of a treatment facility. Figure 6 shows the impact of one or more
substance abuse treatment facilities opening within counties with no previous treatment facility,
on the county level opioid related death rate. While there are no visible trends leading up to the
opening(s), the opioid related death rate declines, most prominently 2-5 years after the
opening(s). I restrict the scope of the event studies to substance abuse treatment facilities that
accept Medicaid. Within counties that had no previous treatment facility accepting Medicaid
experiencing one or more openings (figure 7), again no trends appear in the years leading up to
the opening(s). The opening(s) then lead to a decrease in the opioid related death rate.
Next, I apply the event study framework to the opening of treatment facilities offering
MAT. In the years leading up to the opening of one or more treatment facilities offering some
MAT (figure 8) in counties with no facility offering MAT, no effect appears. The opioid related
death rate then declines in years 1-4 after the opening(s). In figure 9, I examine counties that
experience a single opening of a treatment facility offing MAT and accepting Medicaid. Prior to
the opening, no effect appears. A small decrease in the opioid death rate appears following the
opening, however, confidence intervals are large and contain a zero-coefficient estimate. Finally,
in figures 10 and 11, I apply both event study frameworks to facilities offering two of more
forms of MAT. Throughout the event studies, coefficient estimates are close to zero in the years
leading up to the opening of a treatment facility across facility types. While the event studies do
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restrict the identifying variation, they offer evidence in support of the validity of the
identification strategy used throughout this study.
5.3 Robustness
In table A1, it appears that the primary results presented in this study are robust when
estimated using alternate measures of the outcome variable, unweighted models and to different
functional forms. These alternate specifications include the natural log transformation of the
opioid related death rate (panel A)8, unweighted OLS (panel B) and population weighted Poisson
models (panel C).9 Next, I test potential reverse causality of this relationship between treatment
facilities and the opioid related death rate. I construct an indicator variable equal to one if one or
more treatment facilities has opened in county c in year t and equal to zero otherwise. I estimate
the following linear probability model:
𝑂𝑝𝑒𝑛𝑖𝑛𝑔𝑐,𝑡 = 𝛼 + 𝛽 ∗ 𝑀𝑜𝑟𝑡𝑎𝑙𝑖𝑡𝑦𝑐,𝑡−1 + 𝑋𝑐,𝑡 𝛾 + 𝛿𝐶 + 𝜌𝑡 + 𝜃𝑐,𝑡 + 𝜖𝑐,𝑡

(3)

Table A7 presents the results from the test of reverse causality. I present estimates from equation
3 with a one and a two-year lag of the measure of the opioid related death rate. I find two
significant result of opposite sign from twelve total specifications. Overall, the county level
opioid related death rate was not found to predict the opening of treatment facilities. Next, I
examine the potential for changes in the composition of the county population in response to the
opening/closing of treatment facilities. In table A8, I put county demographic measures on the

8

One is added to the opioid related death rate prior to the log transformation to avoid missing observations
Poisson regressions are estimated using the ppmlhdfe Stata command developed by Correia et al. (2019) while
OLS regressions are estimated using reghdfe Stata command developed by Correia (2017)
9
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left-hand side and find that overall, the opening/closing of treatment facilities does not explain
any potential compositional changes in the county population.
5.4 Heterogeneity
In table 7, I compare substance abuse treatment taking place in Florida to the rest of the
U.S. In 5 of 6 specifications, the coefficient of interest is positive when the sample is restricted to
counties within Florida and negative when the sample consists of all counties outside of Florida.
These results may be indicative of the perverse incentives created by the ACA and MHPAEA.
While these results do not provide an identification strategy to test for fraud in the treatment
industry in Florida, they are suggestive of such effects. There are accounts of fraud in the
treatment industry in the media on a case by case basis but no published research of broader
scope to date (Seville et al., 2017).
In table A2, I explore the heterogeneity of these effects by gender. The opening of a
treatment facility offering some MAT and accepting Medicaid has the largest negative impact on
the opioid related death rate of females. The opening of such a treatment facility has less of an
impact of the male opioid related death rate. The population weighted mean male opioid related
death rate is about twice that of the female opioid related death rate. In table A3, I explore the
heterogeneity of these effects by race. When considering the white and black opioid related death
rates, again, the most effective type of treatment facility appears to be facilities offering MAT
and accepting Medicaid. The weighted mean white opioid related death rate is about twice that of
the black death rate and the Hispanic death rate. Finally, I explore the heterogeneity of these
effects by county size. I split the data by county population categorizing counties as urban,
medium or rural. In table A4, it appears that treatment facility openings have a larger negative
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impact in rural counties though the coefficient of interest is no longer significant. This may be
explained by a lack of identifying variation as there are fewer openings in rural counties
throughout the sample period.
5.5 Other Economic Outcomes
Given the economic cost of the opioid epidemic, changes in treatment capacity may
impact local economic outcomes. In table A5, I consider the impact of treatment facilities on the
labor force participation rate using two different measures. The first measure of the labor force
participation rate comes from the ACS Employment Status 1-Year Estimates. This dataset does
not include every county in the US. The second measure contains the majority of US counties. It
was constructed by the author taking the county labor force as a count, obtained from the BLS,
and dividing by the county level working age population from the NCHS. Using both measures,
treatment facilities appear to have a positive economic impact on the communities they serve.
Facilities offering MAT and accepting Medicaid led to the largest increases in the labor force
participation rate. The opening of one such facility is estimated to increase the labor force
participation rate by about 0.08-0.09 percent. In table A6, I consider a number of measures of
income from the ACS Income in the past 12 months 1-Year Estimates. While the effect size is
small, the opening of a treatment facility appears to have a positive impact on median and mean
county income.

6. Conclusion
In this study, I find that the opening of a substance abuse treatment facility has a negative
impact on the opioid related death rate within the county of the opening. There is substantial
heterogeneity when comparing different types of treatment facilities. The opening of a treatment
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facility offering at least some form of MAT and accepting Medicaid is estimated to reduce the
county opioid related death rate by about 0.9 to 1.1 percent while the opening of any other type
of treatment facility does not have a statistically significant impact. Treatment facilities
accepting Medicaid and offering MAT were also found to have a larger positive impact on
treatment admissions rates and on local economic outcomes.
Mental health parity legislation along with the ACA has increasing the prominence of
public and private insurance in providing funding for treatment of SUD. Medicaid is the single
largest payer for mental health services in the U.S. (Centers for Medicare and Medicaid Services,
2019). From the perspective of a patient seeking treatment for OUD, increasing treatment
capacity can remove or reduce some of the barriers to receiving treatment that patient may face.
These barriers could include cost related to distance/travel, insurance type mismatch or a lack of
services available to treat OUD. Results presented in this paper suggest that the existing capacity
for treatment of OUD in the U.S. may not be sufficient. Specifically, this applies to Medicaid
beneficiaries seeking treatment for OUD.
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8. Tables and Figure
Table 1
Summary Statistics
Variable
Mean
Std. Dev
Facilities Providing Substance Abuse Services
39.24
77.29
Facilities Providing Substance Abuse Services and Accepting
16.96
27.58
Medicaid
Facilities Providing Some Medication Assisted Treatment
9.73
17.50
Facilities Providing Some Medication Assisted Treatment and
5.80
10.86
Accepting Medicaid
Facilities Providing at Least Two Different Forms of
6.19
12.46
Medication Assisted Treatment
Facilities Providing at Least Two Different Forms of
1.81
4.24
Medication Assisted Treatment and Accepting Medicaid
Facilities Providing Buprenorphine
4.58
9.24
Facilities Providing Buprenorphine and Accepting Medicaid
2.53
5.55
Facilities Providing Methadone
4.58
8.91
Facilities Providing Methadone and Accepting Medicaid
3.10
6.80
7.52
7.08
All Opioids Death rate per 100k
0.21
0.03
Fraction Ages 0-15
0.26
0.04
Fraction Ages 16-35
0.39
0.03
Fraction Ages 35-64
0.51
0.01
Fraction Female
0.79
0.15
Fraction White
0.13
0.14
Fraction Black
6.74
2.63
Unemployment Rate
10.62
0.28
Log Per Capita Income
0.66
0.05
Labor Force Participation Rate (ACS Employment)
0.63
0.06
Labor Force Participation Rate (BLS)
61,586
15,644
Median Household Income
38,221
10,065
Median Non-Family Household Income
82,323
20,446
Mean Household Income
52,275
13,419
Mean Non-Family Household Income
Notes: Data: 2005-2016. Summary statistics are weighted by county population.
Florida excluded from sample. Data sources: N-SSATS, NAPHSIS, NCHS, ACS,
BLS, BEA
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Table 2
Treatment Facilities Offering MAT

County FE and Year FE
N
Include State by Year FE
N
Include Demographic Controls
N

Facilities
Providing Some
MAT

Facilities
Providing MAT
and Accepting
Medicaid

Facilities
Providing Two or
More Forms of
MAT

-0.00629***
(0.00125)
33,798

-0.00608*
(0.00318)
33,798

-0.00191**
(0.000795)
33,798

Facilities Providing
Two plus forms of
MAT and
Accepting
Medicaid
-0.00698*
(0.00388)
33,798

-0.00293
(0.00248)
33,769

-0.00945***
(0.00360)
33,769

-0.00137
(0.00117)
33,769

-0.0112***
(0.00397)
33,769

-0.00229
(0.00252)
33,769

-0.00884***
(0.00336)
33,769

-0.00115
(0.00112)
33,769

-0.00975**
(0.00401)
33,769

-0.00231
-0.00892***
-0.00112
-0.00958**
Include Controls for
(0.00261)
(0.00342)
(0.00113)
(0.00413)
Economic Conditions
33,197
33,197
33,197
33,197
N
Mean of Dependent Before
7.52
7.52
7.52
7.52
Transformation
Notes: Dependent variable - Inverse Hyperbolic Sine transformation of opioid death rate per 100,000. Inclusion of
controls and fixed effects varied by row. Treatment facilities are a count variable per county per year by type of
facility. These estimates are weighted by county population. Standard errors in parenthesis are adjusted for clustering
at the county level. * p<0.10, ** p<0.05, *** p<0.01
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Table 3
Treatment Facilities Classified by Medication Offered

County FE and Year FE
N
Include State by Year FE
N
Include Demographic Controls
N

Facilities
Offering
Buprenorphine

Facilities Offering
Buprenorphine and
Accepting
Medicaid

Facilities Offering
Methadone

Facilities Offering
Methadone and
Accepting Medicaid

-0.00266
(0.00168)
33,809

-0.00768***
(0.00178)
33,809

0.00383*
(0.00206)
33,809

0.00198
(0.00329)
33,809

-0.00435***
(0.00123)
33,776

-0.00862***
(0.00147)
33,776

0.000103
(0.00218)
33,776

0.000962
(0.00328)
33,776

-0.00410***
(0.00118)
33,776

-0.00810***
(0.00140)
33,776

-0.00124
(0.00197)
33,776

-0.000736
(0.00308)
33,776

-0.00391***
-0.00770***
-0.000976
-0.000398
Include Controls for
(0.00126)
(0.00146)
(0.00196)
(0.00305)
Economic Conditions
33,204
33,204
33,204
33,204
N
Mean of Dependent Before
7.52
7.52
7.52
7.52
Transformation
Notes: Dependent variable - Inverse Hyperbolic Sine transformation of opioid death rate per 100,000. Inclusion of
controls and fixed effects varied by row. Treatment facilities are a count variable per county per year by type of facility.
These estimates are weighted by county population. Standard errors in parenthesis are adjusted for clustering at the county
level. * p<0.10, ** p<0.05, *** p<0.01
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Table 4
Comparing Treatment Facilities to all others not of the Type
Facilities of that
Type
Panel A
-0.00892***
Facilities Offering Some MAT
(0.00342)
and Accepting Medicaid

All other Facilities Not
of that Type
-0.000811
(0.00102)

Panel B
Facilities Offering at least 2 Forms
of MAT and Accepting Medicaid

-0.00958**
(0.00413)

-0.000999
(0.000976)

Panel C
Facilities Offering Buprenorphine
and Accepting Medicaid
N
Mean

-0.00770***
(0.00146)
33,197
7.52

-0.000652
(0.00112)
33,197
7.52

Notes: Dependent variable - Inverse Hyperbolic Sine transformation of opioid death rate per
100,000. Controls include the fraction of the county population that are white, black, female, ages
0-15, ages 16-34 and ages 35-64 years old, the unemployment rate and the natural log of per capita
income. Treatment facilities are a count variable: number in a county by year. Models include
county, year and state by year fixed effects. These estimates are weighted by county population.
Standard errors in parenthesis are adjusted for clustering at the county level. * p<0.10, ** p<0.05,
*** p<0.01
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Table 5
Opioid Use Treatment Admissions Rate by Primary Substance Abuse Problem - State Year
Level Data
Facilities
Substance
SA Facilities
Facilities
Providing
Abuse
Accepting
Providing
MAT and
Facilities
Medicaid
Some MAT
Accepting
Medicaid
-0.117
-0.0361
0.0750
0.192***
Panel A: All Opiates
(0.108)
(0.150)
(0.101)
(0.0620)
498
498
498
498
N
144.91
144.91
144.91
144.91
Mean
Panel B: Heroin
N
Mean

-0.0900
(0.0925)
493
100.63

-0.0835
(0.102)
493
100.63

-0.00277
(0.0588)
493
100.63

0.00196
(0.0650)
493
100.63

0.218*
(0.110)
498
144.91

Facilities
Providing Two
plus forms MAT
and Accepting
Medicaid
0.486**
(0.213)
498
144.91

0.129
(0.0957)
493
100.63

0.335*
(0.167)
493
100.63

Facilities
Providing Two
or More Forms
of MAT

-0.0285
0.0455
0.0747
0.182***
0.0858
0.144**
Panel C: Other Opiates
(0.0356)
(0.0577)
(0.0775)
(0.0506)
(0.0652)
(0.0604)
Excluding Methadone
497
497
497
497
497
497
N
43.53
43.53
43.53
43.53
43.53
43.53
Mean
Notes: Dependent variable - treatment admission rate per 100,000 where primary substance abuse problem is opioid use. Controls
include the fraction of the state population that are white, black, ages 0-15, ages 16-34 and ages 35-64 years old and the unemployment
rate. Treatment facilities are a count variable per state per year by type of facility. Models include state and year fixed effects. These
estimates are weighted by state population. Standard errors in parenthesis are adjusted for clustering at the state level. * p<0.10, **
p<0.05, *** p<0.01
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Table 6
Opioid Use Disorder Treatment Admissions Rate - Core Based Statistical Area

Panel A
Admissions Involving MAT
N
Mean

Substance
Abuse
Facilities

SA Facilities
Accepting
Medicaid

Facilities
Providing
Some MAT

-0.0829
(0.106)
1,362
45.61

-0.227**
(0.114)
1,362
45.61

0.409***
(0.134)
1,362
45.61

Facilities
Providing
MAT and
Accepting
Medicaid
0.599***
(0.134)
1,362
45.61

Facilities
Providing Two
or More Forms
of MAT
0.158
(0.152)
1,362
45.61

Facilities
Providing Two
plus forms MAT
and Accepting
Medicaid
0.289***
(0.0368)
1,362
45.61

-0.193
-0.283
0.120
0.114
0.0101
0.0632
Panel B
(0.149)
(0.186)
(0.238)
(0.350)
(0.200)
(0.123)
Admissions for OUD
1,362
1,362
1,362
1,362
1,362
1,362
N
154.96
154.96
154.96
154.96
154.96
154.96
Mean
Notes: Dependent variable - treatment admission rate per 100,000 where primary substance abuse problem is opioid use. Treatment
facilities are a count variable per CSBA per year by type of facility. Models include Core Based Statistical Area (CBSA) and year fixed
effects. These estimates are weighted by CSBA population. Standard errors in parenthesis are adjusted for clustering at the CSBA level.
* p<0.10, ** p<0.05, *** p<0.01
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Table 7
Comparing Florida to the Rest of the U.S.

Panel A: Florida
N
Mean

Substance
Abuse
Facilities

SA Facilities
Accepting
Medicaid

Facilities
Providing
Some MAT

0.0162**
(0.00737)
737
8.28

0.0260*
(0.0153)
737
8.28

0.0281***
(0.00920)
737
8.28

Facilities
Providing
MAT and
Accepting
Medicaid
0.0511
(0.0348)
737
8.28

Facilities
Providing Two or
More Forms of
MAT
0.0260***
(0.00741)
737
8.28

Facilities
Providing Two
plus forms MAT
and Accepting
Medicaid
0.0960*
(0.0526)
737
8.28

-0.00157**
-0.000350
-0.00231
-0.00892***
-0.00112
-0.00958**
(0.000749)
(0.00143)
(0.00261)
(0.00342)
(0.00113)
(0.00413)
33,197
33,197
33,197
33,197
33,197
33,197
N
7.52
7.52
7.52
7.52
7.52
7.52
Mean
Notes: Dependent variable - Inverse Hyperbolic Sine transformation of opioid death rate per 100,000. Controls include the fraction
of the county population that are: white, black, female, ages 0-15, ages 16-34 and ages 35-64 years old, the unemployment rate and
log per capita income. Models include county FE and year FE. Treatment facilities are a count variable: number in a county by
year. These estimates are weighted by county population. Standard errors in parenthesis are adjusted for clustering at the county
level. * p<0.10, ** p<0.05, *** p<0.01
Panel B: Rest of U.S.
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Figure 1: All Substance Abuse Facility Openings (2005-2016)

Notes: Data - SAMHSA N-SSATS Directories 2005-2016
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Figure 2: Substance Abuse Facilities offering Some MAT Openings (2005-2016)

Notes: Data - SAMHSA N-SSATS Directories 2005-2016
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Figure 3: Substance Abuse Facilities accepting Medicaid Openings (2005-2016)

Notes: Data - SAMHSA N-SSATS Directories 2005-2016
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Figure 4: Treatment Facilities by Type and Opioid Death Rate per 100,000

Notes: All SA Facilities refers to the any facility offering substance abuse treatment. Some MAT
refers to the number of treatment facilities offering any of the three forms of medication assisted
treatment: methadone, buprenorphine, and/or naltrexone. Opioid death rate on left vertical axis
and number of treatment facilities on right vertical axis.
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Figure 5: Coefficient Plot

Notes: Dependent variable – inverse hyperbolic sine transformation of opioid related death rate
per 100,000. Plot of coefficient estimate and 95% confidence interval. Controls include the
fraction of the county population that are white, black, female, ages 0-15, ages 16-34 and ages
35-64 years old, the unemployment rate and the natural log of per capita income. Treatment
facilities are a count variable per county per year by type of facility. Models include county, year
and state by year fixed effects. These estimates are weighted by county population. Standard
errors in parenthesis are adjusted for clustering at the county level.
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Figure 6: Event Study – Impact of substance abuse facility opening

Notes: Dependent variable – inverse hyperbolic sine transformation of opioid related death rate
per 100,000. Event study of counties with no substance abuse treatment facility with one or more
opening throughout 2005-2016. Controls include the fraction of the county population that are
white, black, female, ages 0-15, ages 16-34 and ages 35-64 years old, the unemployment rate and
the natural log of per capita income. Models include county, year and state by year fixed effects.
These estimates are weighted by county population. Standard errors in parenthesis are adjusted
for clustering at the county level.
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Figure 7: Event Study – Impact of substance abuse facility accepting Medicaid
opening

Notes: Dependent variable – inverse hyperbolic sine transformation of opioid related death rate
per 100,000. Event study of counties with no substance abuse treatment facility accepting
Medicaid with one or more opening throughout 2005-2016. Controls include the fraction of the
county population that are white, black, female, ages 0-15, ages 16-34 and ages 35-64 years old,
the unemployment rate and the natural log of per capita income. Models include county, year and
state by year fixed effects. These estimates are weighted by county population. Standard errors in
parenthesis are adjusted for clustering at the county level.
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Figure 8: Event Study – Impact of substance abuse facility offering some MAT

Notes: Dependent variable – inverse hyperbolic sine transformation of opioid related death rate
per 100,000. Event study of counties with no substance abuse treatment facility offering MAT
with one or more opening throughout 2005-2016. Controls include the fraction of the county
population that are white, black, female, ages 0-15, ages 16-34 and ages 35-64 years old, the
unemployment rate and the natural log of per capita income. Models include county, year and
state by year fixed effects. These estimates are weighted by county population. Standard errors in
parenthesis are adjusted for clustering at the county level.
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Figure 9: Event Study – Impact of substance abuse facility offering some MAT and
accepting Medicaid opening

Notes: Dependent variable – inverse hyperbolic sine transformation of opioid related death rate
per 100,000. Event study of counties with a single opening of a treatment facility offering MAT
and accepting Medicaid throughout 2005-2016. Controls include the fraction of the county
population that are white, black, female, ages 0-15, ages 16-34 and ages 35-64 years old, the
unemployment rate and the natural log of per capita income. Models include county, year and
state by year fixed effects. These estimates are weighted by county population. Standard errors in
parenthesis are adjusted for clustering at the county level.
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Figure 10: Event Study – Impact of substance abuse facility offering Two plus
forms of MAT opening

Notes: Dependent variable – inverse hyperbolic sine transformation of opioid related death rate
per 100,000. Event study of counties with a single opening of a treatment facility offering two
plus forms of MAT throughout 2005-2016. Controls include the fraction of the county
population that are white, black, female, ages 0-15, ages 16-34 and ages 35-64 years old, the
unemployment rate and the natural log of per capita income. Models include county, year and
state by year fixed effects. These estimates are weighted by county population. Standard errors in
parenthesis are adjusted for clustering at the county level.
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Figure 11: Event Study – Impact of substance abuse facility offering Two plus
forms of MAT opening

Notes: Dependent variable – inverse hyperbolic sine transformation of opioid related death rate
per 100,000. Event study of counties with no substance abuse treatment facility offering two plus
forms of MAT with one or more opening throughout 2005-2016. Controls include the fraction of
the county population that are white, black, female, ages 0-15, ages 16-34 and ages 35-64 years
old, the unemployment rate and the natural log of per capita income. Models include county,
year and state by year fixed effects. These estimates are weighted by county population. Standard
errors in parenthesis are adjusted for clustering at the county level.
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Figure 12: Annual Admissions by Primary Substance Use 2006-2016

Notes: Data - SAMHSA TEDs Admissions 2006-2016
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Chapter 3. The Introduction of Abuse-Deterrent Opioids and Rates of Viral
Infection
1. Introduction
The opioid epidemic has elicited responses from pharmaceutical companies, the Food and
Drug Administration (FDA) and from federal, state and local governments. Many responses to
the opioid epidemic have focused on the supply of prescription opioids. The FDA is encouraging
pharmaceutical companies to develop abuse-deterrent versions of opioid analgesics (FDA,
2018a). Recent studies (Alpert et al., 2018; Evans et al., 2019; Powell et al., 2019) have
documented how the introduction of abuse-deterrent OxyContin led to substitution among opioid
users from prescription opioids to illicit heroin. Beyond the immediate risk of overdose, misuse
of opioids may be contributing to increases in rates of viral infection through injection drug use
(IDU). I build on these recent studies by exploring other unintended consequences of the
reformation of prescription opioids. The creation of abuse-deterrent prescription opioids may
increase the likelihood that those with opioid use disorder engage in IDU through substitution
(for example illicit heroin) or through IDU of abuse-deterrent prescription opioids. In this study,
I find that states that had higher prevalence of OxyContin misuse prior to the introduction of
abuse-deterrent OxyContin have experienced increases in the rate of acute hepatitis B virus
(HBV) infection. These states may also be experiencing higher rates of HIV infection though this
analysis faces data limitations.

2. Background
From 1997-2017, there were almost 400,000 overdose deaths involving opioids (CDC,
2018d). The Council of Economic Advisors estimated that the economic cost of the opioid
epidemic in 2015 was $504 billion (The Council of Economic Advisors, 2017). These measures
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may be missing the extent to which the opioid epidemic is impacting rates of viral infection
including hepatitis and HIV. In 2015, almost 20,000 deaths were attributed to the hepatitis C
virus (HCV) (Powell et al., 2019). In 2016, there were almost 16,000 deaths among those
diagnosed with HIV (though these deaths may be due to any cause and may not be attributed to
HIV) (CDC, 2019). About 1,700 deaths were attributed to HBV in 2016 though this is an
underestimate of the true number (CDC, 2018a). The treatment cost over a lifetime associated
with one additional HIV infection is about $380,000 (CDC, 2017) and $205,000 associated with
one additional case of chronic HCV (Razavi et al., 2013). Given these facts, it is important to
understand how the epidemic of drug use in the U.S. has impacted new viral infections. This
understanding could inform policy and prevention efforts going forward.
2.1 Viral Hepatitis
Both HBV and HCV can become chronic infections which remain significant public
health problems throughout the U.S. HCV is responsible for more deaths in the U.S. than any
other infectious disease (Powell et al., 2019). Approximately 75-85% of those infected with
HCV develop chronic HCV while HBV is much more likely to develop into a chronic infection
among infants and children (CDC, 2016). About 5% of infected adults will develop chronic
HBV, 30-50% of children will develop chronic HBV and 90% of infants who receive HBV from
their mother will develop chronic HBV (CDC, 2016). An estimated 850,000 Americans have
chronic HBV (CDC, 2018a). Chronic HBV can lead to liver damage, liver cancer and death.
From 1999-2005, rates of HCV and HBV infections decreased significantly (figure 1). Rates of
HCV infection began to increase in 2005 while rates of HBV infection began to level off around
2008-2009.
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HBV is a viral infection which can be contracted when infected blood, semen, or other
bodily fluid enters the body (CDC, 2018a). Rates of acute HBV declined steadily throughout the
1990’s with the introduction and dissemination of the hepatitis B vaccine (CDC, 2019). As of
2016, about 71% of newborns in the U.S. received the hepatitis B vaccine within the first 3 days
of birth (CDC, 2018c). In the same year, the hepatitis B vaccine covered about 1 out of 4 adults
(CDC, 2018e). The Centers for Disease Control and Prevention (CDC) estimates that there were
20,900 new cases of HBV in 2016 (CDC, 2016). Many people infected with HBV are not aware
that they are infected with the virus (CDC, 2018a).
The population in the U.S. with an opioid use disorder (OUD) is estimated to be to 2.1
million (HHS, 2019). About 886,000 of those are heroin users (HHS, 2019). The increasing
prevalence of OUD has increased the size of the population engaging in IDU. Among the many
risks facing those who engage in IDU is the contraction of a viral disease. The CDC estimates
that from 2003 to 2010 there were approximately 3.5 million new cases of HCV (CDC, 2016).
From 2010-2016, there was a 3.5-fold increase in cases of HCV reported to the CDC (most cases
go unreported) (CDC, 2016). About 60% of new HCV cases are related to IDU (NASTAD,
2018). Many opioid users whose first opioid use came in the form of a prescription pill go on to
use opioids via injection. An estimated 10-20% who misuse prescription opioids will go on to
use prescription opioids or heroin via injection (Van Handel et al., 2016).
The opioid epidemic has been linked to new cases of viral hepatitis. Most new cases of
HBV and HCV have occurred among people who engage in IDU (CDC, 2018d). Zibbell et al.
(2017) examine the Substance Abuse and Mental Health Services Administration’s Treatment
Episode Data Set. The authors find that between 2004 and 2014, admission to treatment for
substance use disorder (SUD) attributed to IDU increased by 76% (Zibbell et al., 2017).
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Suryaprasad et al. (2014) examine follow up interviews conducted with young persons recently
infected with HCV in 2011 and 2012. Among those interviewed, 84% reported ever using drugs
and/or alcohol recreationally (Suryaprasad et al., 2014). Among that subgroup, 74% reported
using OxyContin or oxycodone and 61% reported using heroin (Suryaprasad et al., 2014). Of
those who reported using both heroin and prescription opioids, heroin use started about 2 and a
half years after the first use of prescription opioids (Suryaprasad et al., 2014). Zibbell et al.
(2017) find that the increasing incidence of HCV from 2004 to 2014 mirrored increases in
admission to SUD treatment attributed to injection use of heroin and prescription opioid
analgesics.
Public policy intended to curb the opioid epidemic has often targeted the supply of
opioids. The literature examining these supply side policies has increasingly shown the
unintended consequences including causing those with OUD to seek substitutes for prescription
opioid analgesics. Cicero et al. (2014) analyze survey data of patients entering substance abuse
treatment for heroin dependence and found that 94% of respondents indicated that they used
heroin because prescription opioid analgesics were becoming too difficult or too expensive to
obtain. Further, about half of respondents indicated that if there were no limiting factors, they
would prefer prescription opioid analgesics over heroin (Cicero et al., 2014).
Among the efforts focused on the supply of prescription opioids is the development of
abuse-deterrent formulations of prescription opioids which has been encouraged by the FDA
(FDA, 2018a). Abuse-deterrent formulations generally seek to target known forms of abuse like
crushing and snorting or dissolving and injecting (FDA, 2018a). OxyContin has been one of the
most widely misused prescription opioids (Cicero et al., 2005). OxyContin sales exceeded $3
billion in 2010 (Alpert et al., 2018). The introduction of abuse-deterrent OxyContin in 2010 led
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to a decrease in the distribution of OxyContin and a decrease in the misuse of OxyContin (Alpert
et al., 2018).
However, the introduction of abuse-deterrent OxyContin also led to substitution across
opioid types among opioid users. This substitution was particularly problematic in states with
higher rates of OxyContin misuse prior to reformulation. Powell et al. (2019) show that the
introduction of abuse-deterrent OxyContin had the additional consequence of increasing rates of
HCV. States with rates of OxyContin misuse above the median experienced 222% growth in
rates of HCV while states below the median experienced 75% growth in rates of HCV (Powell et
al., 2019). In states that received oxycodone (the active ingredient in OxyContin) shipments per
capita above the median, the monthly heroin related death rate per 100,000 increased from about
0.1 to 0.4 by 2014 (Evans et al., 2019). In states below the median, the monthly heroin related
death rate also increased but did not exceed 0.25 by 2014 (Evans et al., 2019). Alpert et al.
(2018) find that a one percentage point increase in OxyContin misuse prior to reformulation led
to an increase of 2.5 additional heroin deaths per 100,000. Prior to reformulation, OxyContin was
typically misused by crushing the pills which enabled chewing, snorting or injecting them
(Alpert et al. 2018). To the extent that the reformulation of OxyContin led users to substitution
across opioid types, the reformulation of OxyContin may have led to more IDU.
2.2 HIV
While new HIV diagnoses have declined nationally, new cases have been linked to IDU.
According to the CDC: “About 1 in 10 new HIV diagnoses in the United States are attributed to
injection drug use or male-to-male sexual contact and injection drug use” (CDC, 2018b). 2015
was the first year in over two decades in which the number of HIV diagnoses attributed to IDU
increased (Dawson and Kates, 2018). Among those who engage in IDU, comorbidity rates
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between HIV and HCV are high. Of those with HIV who engage in IDU, about 80% also have
HCV (NASTAD, 2018). Chronic pain is more prominent among those infected with HIV
(Cunningham, 2018). Estimates suggest that about 21% to 53% of individuals with HIV are
prescribed opioids and that patients with HIV are prescribed opioids in higher doses
(Cunningham, 2018). Compared to the general population, those infected with HIV are more
likely to have a SUD (Cunningham, 2018).
Opana ER was a high strength prescription opioid produced by Endo Pharmaceuticals.
Similar to OxyContin, Endo Pharmaceuticals replaced Opana ER with an abuse-deterrent
formula in 2012. Here is a description of the properties of the abuse-deterrent product from the
FDA: “The product, currently marketed by Endo Pharmaceuticals, is a reformulation of the
original product, designed with physicochemical properties intended to make the drug resistant
to physical and chemical manipulation for abuse by snorting and injecting“ (FDA, 2018b). Peters
et al. (2016) identified 181 diagnosed cases of HIV infection in Indiana from 2014-2015. About
88 percent of these patients reported IDU of extended release Oxymorphone (Opana ER) (Peters
et al., 2016). In June of 2017, the FDA requested Endo Pharmaceuticals remove Opana ER from
the marketplace (FDA, 2017).
Figure 9 shows the HIV diagnoses rate in the state of Indiana. In the years following the
release of abuse-deterrent Opana, Indiana experienced a massive spike in HIV diagnoses.
Interviews conducted in Austin, IN, the town at the center of the HIV outbreak, revealed how the
reformulation of Opana ER may have played a role. Prior to reformulation, Opana was misused
by crushing pills and then snorting, bypassing the prescription’s time release (Herald, 2016).
When the abuse-deterrent version was introduced, these users switched from crushing and
snorting Opana to cooking the prescription for injection use (Herald, 2016). These interviews
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suggest that the release of abuse-deterrent Opana had the unintended consequence of leading to
increased IDU which increased the potential spread of viral disease. While the release of abusedeterrent OxyContin had nationwide repercussions, misuse of Opana was much less widespread
prior to reformulation. Oxycodone is the active ingratiate in OxyContin while oxymorphone is
the active ingredient in Opana. In 2008, about 250 grams of oxymorphone were distributed in the
U.S. per 100,000 people compared to about 12,450 grams of oxycodone per 100,000 people
(DEA ARCOS, 2008).

3. Data
Data regarding rates of HIV and viral hepatitis infection come from the Centers for
Disease Control and National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
(NCHHSTP). The NCHHSTP data contain the infection rate per 100,000 at the state year level
including: HIV, HBV and HCV. The explanatory variable of interest measures the amount of
nonmedical use of OxyContin by state prior to the reformulation of OxyContin. These data were
obtained from Alpert et al., (2018). The authors constructed the measure using data from the
National Survey on Drug Use and Health. As a secondary measure, misuse of OxyContin is
measured using shipments of prescription opioid analgesics. These data come from the Drug
Enforcement Agency (DEA) Automation of Reports and Consolidated Orders System (ARCOS)
Retail Drug Summary Reports.
A set of control variables used in the study include demographic data, economic data and
data regarding changes in state policy. Population and demographic data come from the National
Center for Health Statistics (NCHS) Bridged-Race Population Estimates. The demographic
controls include the share of the state population that are ages 0-15, ages 16-35, ages 36-64,
female, white and black. Data regarding the unemployment rate comes from the Bureau of Labor
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Statistics (BLS) Local Area Unemployment Statistics (LAUS). The implementation dates of
Prescription Drug Monitoring Programs (PDMP) were obtained from Kilby (2015) and the
National Alliance for Model State Drug Laws (2018). Effective dates of PDMPs with physician
mandates come from Buchmueller and Carey (2018). Effective dates of state Pain Clinic Laws
were obtained from Meinhofer and Witman (2018).

4. Identification Strategy
The identification strategy used in this study was developed by Alpert et al. (2018). This
model exploits variation in the prevalence of OxyContin misuse at the state level prior to the
reformulation of OxyContin. First, the following event study model is estimated:
′
𝑌𝑠,𝑡 = 𝛼 + 𝛽 ∗ 𝜌𝑇 ∗ 𝑂𝑥𝑦𝑅𝑎𝑡𝑒𝑠𝑃𝑟𝑒 + 𝑋𝑠,𝑡
𝛾 + 𝛿𝑆 + 𝜆 𝑇 + 𝜖𝑠,𝑡

(1)

Where 𝑌𝑠,𝑡 is the rate of viral infection per 100,000 in state s in year t. 𝑂𝑥𝑦𝑅𝑎𝑡𝑒𝑠𝑃𝑟𝑒 is the rate of
OxyContin misuse in state s prior to the reformulation of OxyContin. This measure is interacted
′
with a set of year dummies. 𝑋𝑠,𝑡
is a vector of control variables including state level demographic

information, the state unemployment rate and changes in state law relating to the opioid
epidemic. 𝛿𝑆 represents the state fixed effects and 𝜆 𝑇 represents the year fixed effects.
Next, I estimate the following trend break model following Alpert et al. (2018):

𝑌𝑠,𝑡 = 𝛼 + 𝛽1 [𝑃𝑜𝑠𝑡𝑡 ∗ 𝑂𝑥𝑦𝑅𝑎𝑡𝑒𝑠𝑃𝑟𝑒 ] + 𝛽2 [𝑡 ∗ 𝑂𝑥𝑦𝑅𝑎𝑡𝑒𝑠𝑃𝑟𝑒 ] + 𝛽3 [𝑃𝑜𝑠𝑡𝑡
′
∗ (𝑡 − 2011) ∗ 𝑂𝑥𝑦𝑅𝑎𝑡𝑒𝑠𝑃𝑟𝑒 ] + 𝑋𝑠,𝑡
𝛾 + 𝛿𝑆 + 𝜖𝑠,𝑡

(2)

𝑃𝑜𝑠𝑡𝑡 is an indicator variable equal to 1 in the year 2011 and subsequent years and equal to zero
otherwise, capturing the impact of the reformulation of OxyContin. 𝑡 represents a linear time
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trend. With respect to estimation of both equations 1 and 2, standard errors are adjusted for
clustering at the state level. Estimates are weighted by state population.

5. Results
Figure 2 is a replication of Exhibit 2 from Powell et al. (2019). This evidence in Powell et
al. (2019) shows that higher rates of OxyContin misuse prior to reformulation were associated
with higher rates of HCV infection in the years following reformulation. In figure 3, I apply the
same empirical strategy and find similar trends with respect to HBV infection rates. There does
not appear to be any relationship between OxyContin misuse and rates of HBV or HCV infection
prior to reformulation. However, following reformulation in 2010, states with higher levels of
OxyContin misuse in the pre-reform period experienced significantly higher growth in the HBV
infection rate. In figure 4, I consider the HIV infection rate. Unfortunately, the CDC NCHHSTP
data of HIV diagnoses does not contain records prior to 2008. The 2009 event study coefficient
estimate is normalized to zero leaving only one year of pre-reform data. In the post reformulation
years, confidence intervals are large and coefficient estimates are positive. There is insufficient
evidence in the event study to suggest that states with higher levels of OxyContin misuse prior to
reformulation experienced higher rates of HIV infection.
In figures 5-8, I utilize a secondary measure of OxyContin misuse in the pre-reform
period. Following Evans et al. (2019), I categorize states that received oxycodone shipments per
100,000 residents above the median and below the median in 2008 based on DEA ARCOS data.
In figure 5, it appears that states above and below the median were following similar trends with
respect to HCV infection rates. Both states above and below the median experience increases in
HCV infection rates immediately following reformulation. However, states above the median
continue to experience growth in HCV infection rates from 2013-2016 while the infection rate
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remains relatively flat in states below the median. In figure 6, it appears that states above and
below the median were following nearly identical trends in terms of HBV infection rates prior to
reformulation. While states below the median continued to experience decreasing HBV infection
rates after the reformulation of OxyContin, states above the median begin experiencing
increasing HBV infection rates. Using the same classification of states, I plot the population
weighted mean number of HIV diagnoses. In figure 7, HIV diagnoses from transmission type
IDU are plotted and in figure 8, HIV diagnoses from transmission type male to male sexual
contact and IDU are plotted. In both cases, states with oxycodone shipments per 100,000 below
the median in 2008 have higher mean HIV diagnoses. Following the introduction of abusedeterrent OxyContin, the mean number of HIV diagnoses declines more rapidly in states below
the median than in states above the median.
In table 2, I estimate the impact of misuse of OxyContin prior to reformulation on rates of
HBV and HIV. Following Alpert et al. (2018), table 2 reports estimates of 𝛽1 + 2 𝛽3 from
equation 2 above. In column 3, the estimates suggest that one additional percentage point of
OxyContin misuse prior to reformulation would lead to 0.376 additional cases of HBV per
100,000 and 3.27 additional cases of HIV per 100,000. In both cases, the OLS results are not
precise and the coefficient of interest is not statistically significant. Table 3 presents the results of
Poisson regression estimation. In the Poisson models, the dependent variable is the number of
cases of viral infection at the state year level. Results in column 3 suggest that a one percentage
point increase in OxyContin misuse prior to reform would result in approximately 2 additional
HBV infections and 1.6 additional HIV infections. For the HBV cases outcome, the coefficient
of interest is statistically significant at the 1% level in the baseline model but is no longer
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significant with the inclusion of a full set of controls. For the HIV cases outcome, the results are
significant at the 1% level in all specifications.
Finally, I examine the heterogeneity of the effect by transmission type, age, gender and
race. In table 4, I test each type of HIV transmission. The largest estimated effect size of
OxyContin misuse prior to reformulation is on HIV diagnoses relating to IDU. The coefficient of
interest is also statistically significant with respect to HIV diagnoses relating to heterosexual and
male-to-male sexual contact. In tables 5 and 6, the impact of OxyContin reformulation is largest
with respect to HIV infections occurring among people between the ages of 25-34, people
between the ages of 45-54, males and blacks.

6. Conclusion
In this study, I build on recent work that has shed light on the large scale, unintended
consequences of the introduction of abuse-deterrent opioids. These papers (Alpert et al., 2018;
Evans et al., 2019; Powell et al., 2019) have shown that the reformulation of OxyContin led to
increases in the heroin related death rate and the HCV infection rate. This study shows that the
increase in the HCV infection rate in states with higher levels of OxyContin misuse coincided
with increases in the HBV infection rate. I test the impact of the reformulation of OxyContin on
rates of HIV infection as well. While these results may be indicative of higher rates of HIV
infection in states with higher rates OxyContin misuse, the results cannot be validated because of
insufficient data in the pre-reform period. Results presented in the paper suggest that many
measures underestimate the true cost of the opioid epidemic. Additional resources many be
needed to prevent further spread of viral disease related to intravenous use of opioids.
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8. Tables and Figures

Figure 1: Rates of Hepatitis

Source: Centers for Disease Control and Prevention National Center for HIV/AIDS, Viral
Hepatitis, STD, and TB Prevention (NCHHSTP)
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Figure 2: Hepatitis C Rate Event Study

Notes: Replication of Powell et al., (2019) Exhibit 4. The outcome variable is the rate of hepatitis
C infections per 100,000 at the state year level. Model includes year fixed effects and state fixed
effects. Controls include age and demographic controls and the unemployment rate and
Prescription Drug Monitoring Programs, PDMPs with a must access clause, and Pain Clinic
Laws. Estimates are weighted by the state population. Standard errors are adjusted for clustering
at the state level.
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Figure 3: Hepatitis B Rate Event Study

Notes: The outcome variable is the rate of hepatitis B infections per 100,000 at the state year
level. Model includes year fixed effects and state fixed effects. Controls include age and
demographic controls and the unemployment rate and Prescription Drug Monitoring Programs,
PDMPs with a must access clause, and Pain Clinic Laws. Estimates are weighted by the state
population. Standard errors are adjusted for clustering at the state level.
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Figure 4: HIV Diagnoses Rate Event Study

Notes: The outcome variable is the rate of HIV diagnoses per 100,000 at the state year level.
Model includes year fixed effects and state fixed effects. Controls include age and demographic
controls and the unemployment rate and Prescription Drug Monitoring Programs, PDMPs with a
must access clause, and Pain Clinic Laws. Estimates are weighted by the state population.
Standard errors are adjusted for clustering at the state level.
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Figure 5: Hepatitis C Rate by 2008 Oxycodone Shipments

Notes: Plot of the Hepatitis C rate per 100,000 separating states by Oxycodone shipments
relative to the median using data from DEA ARCOS and NCHHSTP. Vertical line indicates the
year in which the abuse-deterrent formula of OxyContin was introduced.
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Figure 6: Hepatitis B Rate by 2008 Oxycodone Shipments

Notes: Plot of the Hepatitis B rate per 100,000 separating states by Oxycodone shipments
relative to the median using data from DEA ARCOS and NCHHSTP. Vertical line indicates the
year in which the abuse-deterrent formula of OxyContin was introduced.
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Figure 7: HIV Diagnosis by 2008 Oxycodone Shipments, Transmission
Category IDU

Notes: Plot of the HIV diagnosis within transmission category IDU, separating states by
Oxycodone shipments relative to the median using data from DEA ARCOS and NCHHSTP.
Vertical line indicates the year in which the abuse-deterrent formula of OxyContin was
introduced.
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Figure 8: HIV Diagnosis by 2008 Oxycodone Shipments, Transmission
Category Male to Male Sexual Contact and IDU

Notes: Plot of the HIV diagnosis within transmission category male to male sexual contact and
IDU, separating states by Oxycodone shipments relative to the median using data from DEA
ARCOS and NCHHSTP. Vertical line indicates the year in which the abuse-deterrent formula of
OxyContin was introduced.

107

Figure 9: Rate of HIV Diagnoses in Indiana

Notes: Plot of the HIV Diagnoses rate per 100,000 in the state of Indiana. Vertical line indicates
the year in which the abuse-deterrent formula of Opana ER was introduced.
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Table 1
Summary Statistics
Variable
Mean
Std. Dev
Hepatitis B Rate per 100,000
1.73
1.26
Hepatitis B Cases
219.86
235.65
Hepatitis C Rate per 100,000
0.42
0.85
Hepatitis C Cases
47.08
65.03
HIV Diagnoses Rate per 100,000
16.79
9.95
HIV Diagnoses Cases
2,120.54 1,905.46
Initial OxyContin Misuse
0.57
0.22
0.22
0.02
Fraction Ages 0-15
0.26
0.01
Fraction Ages 16-35
0.39
0.02
Fraction Ages 35-64
0.80
0.09
Fraction White
0.13
0.08
Fraction Black
0.51
0.01
Fraction Female
0.48
0.50
Prescription Drug Monitoring Programs
0.03
0.17
Must Access Prescription Drug Monitoring Programs
0.07
0.26
Pain Clinic Laws
Notes: Data - 1999-2016. Summary statistics are weighted by state population.
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Table 2
Impact of OxyContin Reformulation on Viral Disease (OLS)
(1)
(2)
Panel A: Hepatitis B
Initial OxyContin 3-year effect
0.673
0.835
(0.641)
(0.712)
Panel B: HIV
Initial OxyContin 3-year effect
1.658
3.013
(2.825)
(2.865)

(3)
0.376
(0.686)
3.283
(3.578)

Demographic and Economic
No
Yes
Yes
Covariates
No
No
Yes
Controls for State Policy
Notes: Dependent Variable - infection/diagnoses rate per 100,000. Population
weighted OLS regression estimates. Models include year fixed effect and state
fixed effect. Standard errors in parentheses are adjusted for clustering at the state
level. * p<0.10, ** p<0.05, *** p<0.01
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Table 3
Impact of OxyContin Reformulation on Viral Disease (Poisson)
(1)
(2)
Panel A: Hepatitis B
Initial OxyContin 3-year effect
1.343***
1.143
(0.412)
(0.386)
Panel B: HIV
Initial OxyContin 3-year effect
0.377***
0.571***
(0.1454)
(0.1379)

(3)
0.717
(0.4878)
0.495***
(0.143)

Yes
Yes
Yes
Log Population Control
Demographic and Economic
No
Yes
Yes
Covariates
No
No
Yes
Controls for State Policy
Notes: Dependent Variable - new infections/cases of viral disease. Population
weighted Poisson regression estimates. Models include year fixed effect and state
fixed effect. Standard errors in parentheses are adjusted for clustering at the state
level. * p<0.10, ** p<0.05, *** p<0.01
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Table 4
HIV Diagnoses Heterogeneity by Transmission Type

Initial OxyContin 3-year
effect

Log Population Control
Demographic and Economic
Covariates
Policy Covariates

All HIV
Diagnoses

IDU

MM
Sexual
Contact
and IDU

0.500***

0.795**

-0.088

0.450**

0.513***

(0.141)

(0.310)

(0.263)

(0.178)

(0.177)

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

MM
Sexual
Contact

Heterosexual
Contact

Notes: Dependent Variable - new infections/cases of viral disease. Population weighted Poisson
regression estimates. Models include year fixed effect and state fixed effect. Standard errors in
parentheses are adjusted for clustering at the state level. * p<0.10, ** p<0.05, *** p<0.01

Table 5
HIV Diagnoses Heterogeneity by Age Group

Initial OxyContin 3-year effect

Demographic and Economic
Covariates
Policy Covariates

Ages 25-34

Ages 35-44

Ages 45-54

5.867
(3.885)

3.967
(8.344)

5.260
(6.196)

Ages 55
plus
2.614
(1.688)

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Notes: Dependent Variable - infection/diagnoses rate per 100,000. Population weighted OLS
regression estimates. Models include year fixed effect and state fixed effect. Standard errors in
parentheses are adjusted for clustering at the state level. * p<0.10, ** p<0.05, *** p<0.01
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Table 6
HIV Diagnoses Heterogeneity by Race and Gender
Male
Female
Initial OxyContin 3-year effect
5.718
1.496
(4.703)
(2.696)

White
1.515
(1.522)

Black
31.049*
(15.605)

Hispanic
1.615
(5.609)

Demographic and Economic
Yes
Yes
Yes
Yes
Yes
Covariates
Yes
Yes
Yes
Yes
Yes
Policy Covariates
Notes: Dependent Variable - infection/diagnoses rate per 100,000. Population weighted OLS regression
estimates. Models include year fixed effect and state fixed effect. Standard errors in parentheses are
adjusted for clustering at the state level. * p<0.10, ** p<0.05, *** p<0.01
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I. Appendix to Chapter 1
Table A1: State Law Effective Dates
PDMP Date of
Implementation
State

"Must
Access"
PDMP

Naloxone
Access
Laws

Good
Samaritan
Laws

Pain Clinic
Laws
2013

Medical
Marijuana
Laws

Alabama
Alaska

Apr-2007

Jun-2015

Jun-2015

Jan-2012

Mar-2016

Oct-2014

Arizona

Dec-2008

Arkansas

Mar-2013

Jul-2015

Jul-2015

California

Jan-2009

Jan-2008

Jan-2013

Colorado

Feb-2008

May-2013

May-2012

Connecticut

Jul-2008

Oct-2003

Oct-2011

Oct-2012

Mar-2013

Mar-2013

Jul-2010

Apr-2011

D.C.
Delaware
Florida

Aug-2012

Aug-2014

Aug-2013

Oct-2011

Jun-2015

Oct-2012

2010

Georgia

Jul-2013

Apr-2014

Apr-2014

2013

Hawaii

1996

Jun-2016

Jul-2015

Idaho

1998

Jul-2015

Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland

1999

Jan-2010

Jan-2007
Mar-2009
Apr-2011
1999
Jan-2009
Jan-2005
Jan-2014
Aug-2010
1998
Apr-2010
Dec-2005

Apr-2015
May-2016

Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio

2012

2012
2008*

Jun-2013
Aug-2015
Apr-2014
Oct-2013
Aug-2012
Oct-2014
May-2014
Jul-2015

Jul-2011

Jun-2012

Mar-2015
Aug-2014

Jan-2014

2012
2005

Oct-2014
Aug-2012
Jul-2014
Jul-2015

Jun-2014
Jan-2013
Dec-2008
May-2014
2012

Oct-2012
1997
Jan-2012
Aug-2012
1973
Oct-2007
Jan-2007
Oct-2011

2007

2012
2013

2012

May-2015
Oct-2015
Jun-2015
Jul-2013
Apr-2001
Jun-2014
Apr-2013
Aug-2015
Mar-2014

Oct-2015
Sep-2015
May-2013
Jun-2007
Sep-2011
Apr-2013
Aug-2015

Jul-2013
Oct-2010
Jul-2007
Jul-2014

2011
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Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington
West Virginia
Wisconsin
Wyoming

Jul-2006
Sep-2011
2001
Jun-2008
Mar-2012
1990
1989
1997
Apr-2009
Jun-2006
Jan-2012
1995
May-2013
Jan-2004

2011

2013

2012

Nov-2013
Jun-2013
Nov-2014
Jun-2012
Jun-2015
Jul-2016
Jul-2014
Sep-2015
May-2014
Jul-2013
Jul-2013
Jun-2010
May-2015
Apr-2014

Jan-2016
Dec-2014
Jun-2012

Jul-2015
Mar-2014
Jun-2013
Jul-2015
Jun-2010
Jun-2015
Apr-2014

Jan-2006

2012
2009
Jul-2004

2012

Sources: The National Alliance For Model State Drug Laws (2018), Kilby (2015), Buchmueller and Carey (2018),
Rees et al. (2019), Meinhofer and Witman (2018), Baggio et al. (2018). Notes: This measure of PDMP includes
earlier substances monitoring programs. Louisiana started receiving prescription data in 2008 and allowed users to
access PDMP data on Jan 1st 2009.
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Table A2: Robustness to Definition of Treatment and Control
All Opioids

Heroin

Other Opioids

Methadone

Synthetic

Other
Narcotics

N

0.0682
(0.0545)
918

-0.308***
(0.107)
918

0.00212
(0.0809)
918

0.0483
(0.0620)
918

0.107
(0.149)
918

0.0523
(0.0889)
918

(2) Coding following Meinhofer
and Witman (2018)
N

0.1000*
(0.0569)
918

-0.347**
(0.168)
918

0.0520
(0.129)
918

0.146***
(0.0554)
918

-0.00913
(0.192)
918

0.224*
(0.118)
918

(3) Preferred Specification
N

0.0789
(0.0500)
864

-0.348***
(0.122)
864

0.00457
(0.0816)
864

0.0796
(0.0604)
864

0.121
(0.148)
864

0.0127
(0.0897)
864

(4) Preferred Specification
and Drop MA and OR
N

0.0751
(0.0505)
810

-0.320***
(0.121)
810

0.00256
(0.0838)
810

0.0816
(0.0631)
810

0.0983
(0.151)
810

0.0587
(0.0943)
810

(1) Full Sample

Notes: State year level data: 1999-2016. Population weighted Poisson Regression estimates. Models include year fixed effect
and state fixed effect. Controls include pertinent laws (NALs, GSLs, PDMPs, "must access" PDMPs, MMLs and PCLs), age
and demographic controls and the unemployment rate. Standard errors in parentheses are clustered at the state level. * p<0.10,
** p<0.05, *** p<0.01
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Table A3: Methadone Coding Sensitivity Analysis
Poisson

OLS - Inverse
Hyperbolic Sine

(1) Methadone (T40.3) is listed as condition 1-4

0.310***
(0.0878)

0.133**
(0.0589)

OLS - Natural
Log (Death Rate
+ 1)
0.101**
(0.0454)

(2) Methadone (T40.3) is listed as condition 1

0.277***
(0.0912)

0.117**
(0.0557)

0.0894**
(0.0427)

36,120

(3) Methadone (T40.3) is listed as condition 1 excluding
Other Synthetic Narcotics (T40.4) is listed as condition 2-9

0.273***
(0.0907)

0.115**
(0.0552)

0.0880**
(0.0423)

35,327

(4) Methadone (T40.3) is listed as condition 1 excluding
Other Opioids (T40.2) is listed as condition 2-9

0.262***
(0.0907)

0.113**
(0.0562)

0.0867**
(0.0430)

31,799

(5) Methadone (T40.3) is listed as condition 1 excluding
Heroin (T40.1) is listed as condition 2-9

0.275***
(0.0911)

0.116**
(0.0556)

0.0889**
(0.0426)

35,892

(6) Methadone (T40.3) is listed as condition 1 excluding
Other/Unspecified Narcotics (T40.6) is listed as condition 2-9

0.272***
(0.0924)

0.117**
(0.0554)

0.0894**
(0.0425)

35,645

(7) Methadone (T40.3) is listed as condition 1, excluding
any other opioid (ICD-10 code T40.1, T40.2, T40.4, T40.6)
is listed as condition 2-6

0.248***
(0.0911)

0.110*
(0.0551)

0.0846*
(0.0421)

30,634

41,853

41,853

41,853

N

Number of
Deaths
55,484

Notes: County year level data: 2003-2016. Population weighted regression estimates. Models include year fixed effect and state fixed
effect. Expanding states with previous expansion have been dropped from the sample (DC, MN, NJ and WA). Controls include pertinent
laws (NALs, GSLs, PDMPs, "must access" PDMPs, MMLs and PCLs), age and demographic controls and the unemployment rate.
Standard errors in parentheses are clustered at the state level. * p<0.10, ** p<0.05, *** p<0.01
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Table A4: Drop Northeast

Drop New England
N

All Opioids

Heroin

0.00211
(0.0665)
42,987

-0.264*
(0.139)
42,987

Other
Opioids
-0.00146
(0.0737)
42,987

Methadone

Synthetic

0.231**
(0.0998)
42,987

0.202
(0.236)
42,987

Other
Narcotics
0.0154
(0.0859)
42,987

Drop New England,
-0.0476
-0.302*
-0.00469
0.298***
-0.000921
-0.0264
NY, PA, OH and MD
(0.0673)
(0.170)
(0.0713)
(0.107)
(0.215)
(0.0800)
39,613
39,613
39,613
39,613
39,613
39,613
N
Notes: County year level data: 2003-2016. Population weighted Poisson regression estimates. Models include year
fixed effect and state fixed effect. Controls include pertinent laws (NALs, GSLs, PDMPs, "must access" PDMPs,
MMLs and PCLs), age and demographic controls and the unemployment rate. Standard errors in parentheses are
clustered at the state level. * p<0.10, ** p<0.05, *** p<0.01
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Table A5: State and County Level Results - Same Sample Window
All Opioids

Heroin

Other Opioids

Methadone

Synthetic

Other
Narcotics

0.0612
(0.0483)

-0.244**
(0.120)

0.00214
(0.0785)

0.0211
(0.0462)

0.296**
(0.130)

0.0233
(0.137)

Controls for Pertinent Laws

0.0315
(0.0449)

-0.300***
(0.113)

-0.0236
(0.0689)

-0.0168
(0.0536)

0.179
(0.144)

0.0376
(0.0776)

Control for Fentanyl Seizures

-0.0117
(0.0451)
920.28
658

-0.296**
(0.118)
228.65
658

-0.0265
(0.0701)
410.35
658

-0.0211
(0.0585)
163.13
658

0.0944
(0.140)
162.03
658

-0.0345
(0.0697)
108.67
658

0.0741
(0.0780)

-0.0338
(0.233)

0.0609
(0.117)

0.400***
(0.0892)

0.425
(0.291)

-0.314
(0.250)

Controls for Pertinent Laws

0.0184
(0.0664)

-0.247*
(0.127)

0.00187
(0.0718)

0.310***
(0.0878)

0.230
(0.227)

-0.116
(0.103)

Control for Fentanyl Seizures

0.0165
(0.0659)

-0.250*
(0.128)

0.000310
(0.0721)

0.316***
(0.0882)

0.233
(0.226)

-0.119
(0.104)

State Level Data
Baseline

Mean of Dependent
N
County Level Data
Baseline

Mean of Dependent
70.39
21.79
28.95
9.65
11.23
11.35
N
41,853
41,853
41,853
41,853
41,853
41,853
Notes: Data: 2003-2016. Population weighted Poisson regression estimates. Models include year fixed effect and state
fixed effect. Expanding states with previous expansion have been dropped from the sample (DC, MN, NJ and WA).
Controls include the natural log of the state population, age and demographic controls and the unemployment rate.
Standard errors in parentheses are clustered at the state level. * p<0.10, ** p<0.05, *** p<0.01
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Table A6: Impact of Medicaid Expansions on Heroin Deaths - Drop Each Individual Treatment State
Early Expanding States
State
Dropped

N

2014 Expanding States

50 States
+ D.C.
-0.302***

CA

CT

D.C.

MN

NJ

WA

AZ

AR

CO

DE

-0.196

-0.296***

-0.303***

-0.302***

-0.329***

-0.307***

-0.331***

-0.302***

-0.307***

-0.302***

(0.106)

(0.134)

(0.107)

(0.107)

(0.107)

(0.116)

(0.107)

(0.107)

(0.106)

(0.107)

(0.106)

918

900

900

900

900

900

900

900

900

900

900

2014 Expanding States
State
Dropped

N

HI

IL

IA

KY

MD

MA

MI

NV

NH

NM

NY

-0.301***

-0.321***

-0.303***

-0.303***

-0.302***

-0.293***

-0.361***

-0.302***

-0.301***

-0.303***

-0.197**

(0.106)

(0.109)

(0.106)

(0.107)

(0.108)

(0.108)

(0.0910)

(0.106)

(0.106)

(0.106)

(0.0886)

900

900

900

900

900

900

900

900

900

900

900

2014 Expanding States
State
Dropped

Late Expanding States

ND

OH

OR

RI

VT

WV

AK

IN

MT

LA

PA

-0.302***

-0.295**

-0.295***

-0.301***

-0.302***

-0.300***

-0.302***

-0.312***

-0.302***

-0.303***

-0.261**

(0.106)

(0.120)

(0.105)

(0.106)

(0.106)

(0.106)

(0.106)

(0.105)

(0.106)

(0.107)

(0.114)

900
900
900
900
900
900
900
900
900
900
900
N
Notes: Dependent variable: Heroin deaths. State year level data: 1999-2016. Population weighted Poisson regression estimates. Models include year fixed
effect and state fixed effect. Controls include pertinent laws (NALs, GSLs, PDMPs, "must access" PDMPs, MMLs and PCLs), age and demographic controls
and the unemployment rate. Standard errors in parentheses are clustered at the state level. * p<0.10, ** p<0.05, *** p<0.01
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Table A7: Robustness to Functional Form - Negative Binomial
All Opioids

Heroin

Other Opioids

Methadone

Synthetic

Other
Narcotics

Baseline

0.0883
(0.0560)

-0.346**
(0.163)

-0.0495
(0.129)

0.192**
(0.0746)

0.113
(0.114)

0.0241
(0.124)

Controls for Pertinent Laws

0.0616
(0.0561)

-0.399***
(0.143)

-0.0853
(0.113)

0.156***
(0.0549)

0.0263
(0.128)

0.0158
(0.105)

Controls for Fentanyl Seizures

0.0226
(0.0527)

-0.402***
(0.148)

-0.0835
(0.114)

0.161***
(0.0571)

-0.0694
(0.122)

-0.0233
(0.103)

819.74
201.86
362.43
140.14
136.49
112.89
Mean of Dependent
846
846
846
846
846
846
N
Notes: State year level data: 1999-2016. Population weighted Negative Binomial regression estimates. Models include
year fixed effect and state fixed effect. Expanding states with previous expansion have been dropped from the sample
(DC, MN, NJ and WA). Controls include the natural log of the state population, age and demographic controls and the
unemployment rate. Standard errors in parentheses are clustered at the state level. * p<0.10, ** p<0.05, *** p<0.01
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Table A8: Robustness to Estimation of Unweighted Poisson
All Opioids

Heroin

Other Opioids

Methadone

Synthetic

Other
Narcotics

Baseline

0.0828
(0.0656)

-0.217*
(0.132)

-0.0397
(0.0786)

0.129*
(0.0664)

0.220
(0.160)

0.0309
(0.157)

Controls for Pertinent Laws

0.0433
(0.0680)

-0.306***
(0.111)

-0.0720
(0.0795)

0.100*
(0.0570)

0.0879
(0.165)

0.0110
(0.103)

Controls for Fentanyl Seizures

-0.00609
(0.0612)

-0.308***
(0.117)

-0.0797
(0.0815)

0.105*
(0.0587)

-0.0142
(0.150)

-0.0545
(0.106)

819.74
201.86
362.43
140.14
136.49
112.89
Mean of Dependent
846
846
846
846
846
846
N
Notes: State year level data: 1999-2016. Poisson regression estimates. Models include year fixed effect and state fixed effect.
Expanding states with previous expansion have been dropped from the sample (DC, MN, NJ and WA). Controls include the
natural log of the state population, age and demographic controls and the unemployment rate. Standard errors in parentheses are
clustered at the state level. * p<0.10, ** p<0.05, *** p<0.01
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Table A9: Inclusion of ICD-10 Code: T50.9
All Opioids

All Opioids &
T50.9

0.0778
(0.0489)

0.0546
(0.0360)

OLS - Inverse Hyperbolic Sine (Death Rate)
Medicaid Expansion

0.0939
(0.0838)

0.0719
(0.0656)

Natural Log (Death Rate + 1)
Medicaid Expansion

0.101
(0.0852)

0.0721
(0.0661)

846

846

Poisson
Medicaid Expansion

N

Notes: State year level data: 1999-2016. Population weighted regression
estimates. Models include year fixed effect and state fixed effect. Controls include
pertinent laws (NALs, GSLs, PDMPs, "must access" PDMPs, MMLs and PCLs),
age and demographic controls and the unemployment rate. Standard errors in
parentheses are clustered at the state level. * p<0.10, ** p<0.05, *** p<0.01
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II. Appendix to Chapter 2
Table A1
Robustness
Substance
Abuse
Facilities

SA Facilities
Accepting
Medicaid

Facilities
Providing
Some MAT

Panel A: Weighted OLS
Dependent LN(Death Rate + 1)
N
Mean

-0.00117*
(0.000632)
33,197
7.52

-0.0000921
(0.00124)
33,197
7.52

-0.00154
(0.00205)
33,197
7.52

Facilities
Providing
MAT and
Accepting
Medicaid
-0.00661**
(0.00284)
33,197
7.52

Panel B: Unweighted OLS
Dependent IHS(Death Rate)
N
Mean

0.00192
(0.00257)
33,197
7.52

0.00178
(0.00336)
33,197
7.52

-0.00379
(0.00359)
33,197
7.52

-0.00741
(0.00501)
33,197
7.52

-0.000844
(0.000912)
33,197
7.52

Facilities
Providing Two
plus forms MAT
and Accepting
Medicaid
-0.00748**
(0.00344)
33,197
7.52

-0.00162
(0.00203)
33,197
7.52

-0.0122**
(0.00587)
33,197
7.52

Facilities
Providing Two
or More Forms
of MAT

-0.00141**
-0.00103
0.00165
-0.00190
0.000241
-0.00452
Panel C: Weighted Poisson
(0.000560)
(0.000892)
(0.00168)
(0.00238)
(0.000654)
(0.00349)
Dependent Deaths
30,276
30,276
30,276
30,276
30,276
30,276
N
71.59
71.59
71.59
71.59
71.59
71.59
Mean
Notes: Controls include the fraction of the county population that are: white, black, female, ages 0-15, ages 16-34 and ages 35-64 years
old, the unemployment rate and per capita income. Models include county FE, year FE and state by year FE. Treatment facilities are a
count variable: number in a county by year. These estimates are weighted by county population. Standard errors in parenthesis are
adjusted for clustering at the county level. * p<0.10, ** p<0.05, *** p<0.01
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Table A2
Heterogeneity by Gender

Panel A: Male
Mean

Substance
Abuse Facilities

SA Facilities
Accepting
Medicaid

Facilities
Providing
Some MAT

-0.00161**
(0.000761)
10.09

-0.000336
(0.00159)
10.09

-0.00369
(0.00281)
10.09

Facilities
Providing
MAT and
Accepting
Medicaid
-0.0112***
(0.00379)
10.09

Facilities
Providing Two or
More Forms of
MAT
-0.00160
(0.00120)
10.09

Facilities
Providing Two
plus forms MAT
and Accepting
Medicaid
-0.0117***
(0.00415)
10.09

-0.00131
-0.000550
-0.0000794
-0.00543
-0.000351
-0.00818*
(0.00104)
(0.00166)
(0.00258)
(0.00341)
(0.00125)
(0.00470)
5.15
5.15
5.15
5.15
5.15
5.15
Mean
33,197
33,197
33,197
33,197
33,197
33,197
N
Notes: Dependent variable - Inverse Hyperbolic Sine transformation of opioid death rate per 100,000. Controls include the fraction of
the county population that are white, black, female, ages 0-15, ages 16-34 and ages 35-64 years old, the unemployment rate and per
capita income. Models include county FE, year FE and state by year FE. Treatment facilities are a count variable: number in a county by
year. These estimates are weighted by county population. Standard errors in parenthesis are adjusted for clustering at the county level. *
p<0.10, ** p<0.05, *** p<0.01
Panel B: Female
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Table A3
Heterogeneity by Race

Panel A: White
N
Mean
Panel B: Black
N
Mean
Panel C: Hispanic
N
Mean

Substance
Abuse Facilities

SA Facilities
Accepting
Medicaid

Facilities
Providing
Some MAT

Facilities
Providing
MAT and
Accepting
Medicaid

Facilities
Providing Two or
More Forms of
MAT

Facilities
Providing Two
plus forms MAT
and Accepting
Medicaid

-0.00184**
(0.000781)

-0.000502
(0.00153)

-0.00217
(0.00259)

-0.00795**
(0.00357)

-0.00152
(0.00114)

-0.00893**
(0.00406)

33,197
8.75

33,197
8.75

33,197
8.75

33,197
8.75

33,197
8.75

33,197
8.75

0.000425
(0.00144)

-0.00127
(0.00223)

0.000494
(0.00310)

-0.00314
(0.00487)

0.00176
(0.00156)

-0.00500
(0.00573)

33,142
4.62

33,142
4.62

33,142
4.62

33,142
4.62

33,142
4.62

33,142
4.62

0.000862
(0.000926)

-0.000527
(0.00163)

-0.00189
(0.00135)

-0.00437
(0.00282)

-0.000142
(0.00127)

-0.00226
(0.00324)

31,973
3.86

31,973
3.86

31,973
3.86

31,973
3.86

31,973
3.86

31,973
3.86

Notes: Dependent variable - Inverse Hyperbolic Sine transformation of opioid death rate per 100,000. Controls include the fraction of
the county population that are white, black, female, ages 0-15, ages 16-34 and ages 35-64 years old, the unemployment rate and per
capita income. Models include county FE, year FE and state by year FE. Treatment facilities are a count variable: number in a county
by year. These estimates are weighted by county population. Standard errors in parenthesis are adjusted for clustering at the county
level. * p<0.10, ** p<0.05, *** p<0.01
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Table A4
Heterogeneity by County Population

Panel A: Urban
N
Mean
Panel B: Medium
N
Mean

Substance
Abuse Facilities

SA Facilities
Accepting
Medicaid

Facilities
Providing
Some MAT

Facilities
Providing
MAT and
Accepting
Medicaid

Facilities
Providing Two or
More Forms of
MAT

Facilities
Providing Two
plus forms MAT
and Accepting
Medicaid

-0.00163*
(0.000844)
2,493
7.86

-0.00116
(0.00150)
2,493
7.86

-0.000795
(0.00295)
2,493
7.86

-0.00640
(0.00405)
2,493
7.86

-0.000922
(0.00119)
2,493
7.86

-0.00591
(0.00552)
2,493
7.86

0.00641
(0.00651)
7,432
7.4

0.00539
(0.00788)
7,432
7.4

-0.00398
(0.0107)
7,432
7.4

-0.00812
(0.0127)
7,432
7.4

0.00517
(0.00793)
7,432
7.4

0.00726
(0.0193)
7,432
7.4

0.00139
-0.0185
-0.00355
-0.00884
-0.0130
-0.0133
(0.0158)
(0.0165)
(0.0284)
(0.0319)
(0.0317)
(0.0612)
23,126
23,126
23,126
23,126
23,126
23,126
N
6.22
6.22
6.22
6.22
6.22
6.22
Mean
Notes: Dependent variable - Inverse Hyperbolic Sine transformation of opioid death rate per 100,000. Urban counties defined as
counties with mean population greater than or equal to 250,000. Rural counties defined as counties with mean population less than or
equal to 50,000. Controls include the fraction of the county population that are: white, black, female, ages 0-15, ages 16-34 and ages
35-64 years old, the unemployment rate and per capita income. Models include county FE, year FE and state by year FE. Treatment
facilities are a count variable: number in a county by year. These estimates are weighted by county population. Standard errors in
parenthesis are adjusted for clustering at the county level. * p<0.10, ** p<0.05, *** p<0.01
Panel C: Rural
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Table A5
Labor Force Participation Rate

Panel A: ACS
N
Mean

Substance
Abuse Facilities

SA Facilities
Accepting
Medicaid

Facilities
Providing
Some MAT

0.00513*
(0.0000262)
8,307
0.66

0.0177***
(0.0000564)
8,307
0.66

0.0409***
(0.0000620)
8,307
0.66

Facilities
Providing
MAT and
Accepting
Medicaid
0.0819***
(0.000127)
8,307
0.66

Facilities
Providing Two or
More Forms of
MAT
0.0105***
(0.0000247)
8,307
0.66

Facilities
Providing Two
plus forms MAT
and Accepting
Medicaid
0.0853***
(0.000203)
8,307
0.66

0.00195
0.0230*
0.0190
0.0799***
0.000889
0.0921***
Panel B: BLS
(0.0000621)
(0.000133)
(0.000140)
(0.000255)
(0.0000575)
(0.000327)
and NHCS
33,769
33,769
33,769
33,769
33,769
33,769
N
0.63
0.63
0.63
0.63
0.63
0.63
Mean
Notes: Dependent variable - labor force participation rate. Linear probability model coefficients scaled up by 100 for interpretation.
Controls include the fraction of the county population that are white, black, female, ages 0-15, ages 16-34 and ages 35-64 years old, the
unemployment rate and the natural log of per capita income. Treatment facilities are a count variable per county per year by type of
facility. Models include county, year and state by year fixed effects. These estimates are weighted by county population. Standard
errors in parenthesis are adjusted for clustering at the county level. * p<0.10, ** p<0.05, *** p<0.01
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Table A6
Inflation Adjusted Median and Mean Income
Substance
Abuse Facilities

SA Facilities
Accepting
Medicaid

Facilities
Providing
Some MAT

Panel A: Log Median
Household Income
Mean

0.0000202
(0.0000826)
61,585

0.0000219
(0.000166)
61,585

0.000104
(0.000303)
61,585

Facilities
Providing
MAT and
Accepting
Medicaid
-0.000225
(0.000362)
61,585

0.000162*
(0.0000876)
61,585

Facilities
Providing Two
plus forms MAT
and Accepting
Medicaid
0.000595
(0.000447)
61,585

Panel B: Log Median
Non-Family Income
Mean

0.000267**
(0.000107)
38,220

0.000525**
(0.000260)
38,220

0.000417
(0.000283)
38,220

0.000754
(0.000549)
38,220

0.000273**
(0.000135)
38,220

0.000551
(0.000623)
38,220

Panel C: Log Mean
Household Income

0.000122*
(0.0000646)
82,321

0.000214*
(0.000127)
82,321

-0.000166
(0.000238)
82,321

-0.000346
(0.000278)
82,321

-0.0000295
(0.0000604)
82,321

0.000174
(0.000438)
82,321

Facilities
Providing Two or
More Forms of
MAT

0.000255***
0.000423*
0.0000453
0.000204
-0.0000600
0.000207
Panel D: Log Mean
(0.0000980)
(0.000230)
(0.000218)
(0.000374)
(0.000113)
(0.000701)
Non-Family Income
52,275
52,275
52,275
52,275
52,275
52,275
Mean
8,343
8,343
8,343
8,343
8,343
8,343
N
Notes: Dependent variable - log county level mean/median income. Controls include the fraction of the county population that are white,
black, female, ages 0-15, ages 16-34 and ages 35-64 years old, the unemployment rate and the natural log of per capita income.
Treatment facilities are a count variable per county per year by type of facility. Models include county, year and state by year fixed
effects. These estimates are weighted by county population. Standard errors in parenthesis are adjusted for clustering at the county level.
* p<0.10, ** p<0.05, *** p<0.01
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Table A7
Reverse Causality

Panel A: One Year before Opening
Opioid Death Rate per 100,000
N

Substance
Abuse
Facilities

SA Facilities
Accepting
Medicaid

Facilities
Providing
Some MAT

Facilities
Providing
MAT and
Accepting
Medicaid

0.0102
(0.00744)
31,935

0.00224
(0.00499)
31,935

0.000980
(0.00537)
31,935

0.00136
(0.00311)
31,935

Facilities
Providing Two
or More Forms
of MAT

Facilities
Providing Two
plus forms MAT
and Accepting
Medicaid

0.00357
(0.00945)
31,935

0.0123*
(0.00632)
31,935

Panel B: Two Years before Opening
0.00740
0.0124
0.00265
-0.00863**
0.0114
-0.00453
Opioid Death Rate per 100,000
(0.00488)
(0.00877)
(0.00624)
(0.00404)
(0.0104)
(0.00317)
29,152
29,152
29,152
29,152
29,152
29,152
N
Notes: Dependent variable - indicator variable for substance abuse facility openings. Controls include the fraction of the county
population that are: white, black, female, ages 0-15, ages 16-34 and ages 35-64 years old, the unemployment rate and per capita income.
Models include county FE, year FE and state by year FE. These estimates are weighted by county population. Standard errors in
parenthesis are adjusted for clustering at the county level. * p<0.10, ** p<0.05, *** p<0.01
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Table A8
Testing County Population Composition Changes
Substance Abuse
Facilities

SA Facilities
Accepting
Medicaid

Facilities
Providing
Some MAT

Population Share
Ages 16-34

-0.00000881
(0.0000119)

-0.0000450*
(0.0000261)

-0.0000250
(0.0000204)

Population Share
Female

0.00000515
(0.00000322)

0.00000676
(0.00000537)

-0.00000341
(0.00000602)

Population Share
White

0.00000967
(0.0000233)

0.00000669
(0.0000460)

0.000113*
(0.0000654)

Population Share
-0.0000138
-0.0000357
-0.000157***
Black
(0.0000235)
(0.0000480)
(0.0000577)
N
33,197
33,197
33,197
Notes: Dependent variable - share of county population within demographics group.
Controls include the unemployment rate and per capita income. Models include county,
year and state by year fixed effects. These estimates are weighted by county population.
Standard errors in parenthesis are adjusted for clustering at the county level. * p<0.10, **
p<0.05, *** p<0.01
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